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ABSTRACT 
 
Molecular imaging modalities are important tools to evaluate the efficacy of gene 
delivery systems and cell-based therapies. Development and application of these 
modalities will advance our understanding of the mechanism of transgene expression 
and cell fate and functions. Physical gene transfer methods hold many advantages over 
viral vectors among gene therapeutic strategies. Here, we evaluated the efficacy of 
biolistic (“gene gun”) gene targeting to tissues with non-invasive bioluminescence 
imaging (BLI) methods.  Plasmids carrying the firefly luciferase reporter gene were 
transfected into mouse skin and liver using biolistics,  and BLI was measured at various 
time points after transfer.  With optimized DNA loading ratio (DLRs), reporter gene 
expression reached to peak 1day after transfer to mouse skin, and the maximum depth 
of tissue penetration was between 200-300μm. Similar peak expression of reporter 
gene was found in mouse liver but the expression was relatively stable 4-8 days post-
biolistic gene transfer and remained for up to two weeks afterward. Our results 
demonstrated BLI was an efficient strategy for evaluation of reporter gene expression in 
the same animals over a period of up to two weeks in vivo. Different tissues showed 
different expression kinetics, suggesting that this is an important parameter to consider 
when developing gene therapy strategies for different target tissues.  
We also employed BLI to measure differentiation of mouse embryonic stem (ES) 
cells into beating cardiomyocytes in vitro and in vivo.  A subset of these cardiomyocytes 
appears to be derived from an adrenergic lineage that ultimately contribute to 
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substantial numbers of cardiomyocytes primarily on the left side of the heart.  At present, 
it is unclear what the precise role of these cardiac adrenergic cells is with respect to 
heart development, though it is known that adrenergic hormones (adrenaline and 
noradrenaline) are essential for embryonic development since mice lacking them die 
from apparent heart failure during the prenatal period.  To identify and characterize 
cardiac adrenergic cells, we developed a novel mouse genetic model in which the 
nuclear-localized enhanced green fluorescent protein (nEGFP) reporter gene was 
targeted to the first exon of the Phenylethanoamine N-transferase (Pnmt) gene, which 
encodes for the enzyme that converts noradrenaline to adrenaline, and hence serves as 
a marker for adrenergic cells.  Our results demonstrate this knock-in strategy effectively 
marked adrenergic cells in both fetal and adult mice. Expression of nEGFP was found in 
Pnmt-positive cells of the adult adrenal medulla, as expected.  Pnmt-nEGFP expression 
also recapitulated endogenous Pnmt expression in the embryonic mouse heart.  In 
addition, nEGFP and Pnmt expression were induced in parallel during differentiation of 
pluripotent mouse ES cells into beating cardiomyocytes. This new mouse genetic model 
provides a useful new tool for studying the properties of adrenergic cells in different 
tissues.  
We also identified two limitations of the Pnmt-nEGFP model.  One is that the 
amount of nEGFP expressed within individual adrenergic cells was highly variable.  
Secondly, expression of nEGFP in the embryonic heart was of low abundance and 
difficult to distinguish from background autofluorescence.  To overcome these 
limitations, we developed two alternative genetic models to investigate adrenergic cells: 
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(1) Mouse embryonic stem cells, which have been previously targeted with Pnmt-Cre 
recombinase gene, were additionally targeted with a dual reporter plasmid which 
covered both a loxP-flanked cDNA of red fluorescence protein (HcRed) and also EGFP.  
Under the undifferentiated status, cells emit red fluorescence as transcription stops 
before EGFP coding sequence. After differentiation into beating cardiomyoctyes, some 
cells switch fluorescence from red to green, indicating that excision of loxP-flanked 
sequences by Cre since Pnmt had been activated.  (2) A surface marker, truncated low-
affinity nerve growth factor receptor (ΔLNGFR) was used as the reporter gene as cells 
expressing this marker can be enriched by magnetic-activated cell sorting (MACS), a 
potentially efficient way to yield highly purified positive cells at low input abundance in a 
population.  Through a series of subcloning steps, the targeting construct, Pnmt-
ΔLNGFR-Neo-DTA was created and electroporated into 7AC5EYFP embryonic stem 
cells. Correctly targeted cells were selected by positive and negative screening. These 
cells provide a new tool with which to identify, isolate, and characterize the function of 
adrenergic cells in the developing heart, adrenal gland, and other tissues where 
adrenergic cells make important contributions. 
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CHAPTER 1 : INTRODUCTION 
 
Gene therapy continues to hold great potential for treating many different types of 
disease and dysfunction.  Safe and efficient techniques for gene transfer and 
expression in vivo are needed to enable gene therapeutic strategies to be effective in 
patients.  Currently, the most commonly used methods employ replication-defective viral 
vectors for gene transfer, while physical gene transfer methods such as biolistic-
mediated (“gene-gun”) delivery to target tissues have not been as extensively explored. 
Compared with viral vector [1] based therapeutic strategies, non-viral vectors have the 
advantages of simple preparations, tissue-specific expression, lower immunogenic 
responses and less toxicities [2-5]. Among non-viral vector-based gene transfer, 
physical methods, which employ physical forces to make transgene to target cells can 
achieve fast expression.  
Although these methods are intensively studied, there are still short of accurate 
and fast evaluation strategies. For example, for the gene delivery into the mouse heart, 
although naked DNA injection has already been shown as a feasible method to induce 
transgene expression, however, the evaluation was either based on more qualitative 
assay such as β-galactosidase activity (LacZ staining) [6] or based on luciferase 
activities but different animals were used for quantification at various time points after 
gene transfer [7]. For the latter, there could be difficulties to draw conclusions as 
discrepancies could occur among individual animal. This inconsistence could be 
overcome if a technology for evaluation is available to detect the transgene expression 
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dynamically in a same animal. Bioluminescence imaging (BLI) is such a tool which is 
based on detection of light emission produced through catalysis of luciferin by firefly 
luciferase [8, 9]. BLI can efficiently evaluate the efficacy of transgene expression in 
organs non-invasively, such as cell survival, proliferation and migration after stem cell 
engraft into mouse myocardium [10-12]. Thus it will be of high interest to evaluate the 
transfect efficacy of nonviral vector gene delviery, especially by physical forces in vivo 
through BLI. These will highly enrich our knowledge of the characteristics of these 
physical gene transfer methods, and their advantage and limitations, thus laying the 
foundations of specific design for each method and further technical improvements to 
increase the gene expression.  
Here, we will use one of the physical gene delivery technology, biolistic delivery 
“Gene Gun”, a method to utilizes the pressurized gas to propel the metal particles which 
are conjugated with DNA to the target tissues[13-16]. This particle bombardment 
technique has already been extensively used in both in vitro and in vivo studies [17-20], 
at the same time, some of the preclinical and clinical trials are undergoing for skin 
vaccinations and immunizations [21-23]. However, the deeper mechanisms of this gene 
delivery method are still under exploitation. In the present study, we evaluated the 
efficacy of biolistic gene transfer techniques in vivo using BLI.  We hypothesize that: 
Bioluminescence imaging (BLI) can efficiently determine the transfection effects 
of reporter plasmids, pCMV-Luciferase, which were targeted both in vitro 
mammalian cells and in vivo mouse organs (liver and skins).  
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We will perform the following experiments which are evaluated mainly by BLI to 
test this hypothesis: 
1. Transfection through gene gun can yield relative high level of gene expression 
compared with other established methods. 
2. The optimization of the gene gun parameters, especially the DNA Loading Ratio 
(DLR) and helium pressure, are critical for the outcome of transfection in vivo. 
3.  The dynamics of reporter gene expression will be variable concerned with 
various tissues and organs, here mainly referred to mouse liver and skins, and 
BLI can accurately recapitulate these processes.  
4. The depth of DNA-particles penetration and its relationship with gene expression 
(determined by β-galactosidase activity) will be determined using mouse skins for 
further characterization of this delivery method.  
5. In order to expand the BLI application in the evaluation of other nonviral gene 
transfer in vivo, naked plasmid will be injected into mouse heart and the 
transgene expression is measured continuously for the same animal to monitor 
the increase and reduction of expression through BLI. 
In addition, BLI will also be used to characterize a specific mouse embryonic stem cell 
line in which the sodium-calcium exchanger-1 (Ncx-1) promoter driven luciferase 
reporter gene is stably trasnfected.  
Catecholamines, including noradrenalin (norepinephrine) and adrenalin 
(epinephrine) are hormones which exert multiple critical physiological functions. They 
are mainly produced in chromaffin cells of the adrenal medullae of adult adrenal glands 
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which are then secreted into the bloodstream during stress conditions [24]. Dopamine β-
hydroxylase (Dbh) converts dopamine to noradrenaline, and phenylethanolamine n-
methyltransferase (Pnmt) converts noradrenaline to adrenaline. Thus Dbh and Pnm are 
usually used as markers of noradrenalin and adrenalin producing cells.  
However, the locations of catecholamine production are far beyond adrenal 
glands and sympathetic ganglionic neurons, a variety of tissues and organs can 
produce and secret catecholamine through paracrine pathway [25-29]. In the developing 
embryo, however, the major site of production first occurs in the heart [30-32]. These 
adrenergic-derived cells are largely unknown in terms of their functions. Here, we use 
Pnmt as a marker for adrenergic cells and generate various genetic models both in vitro 
and in in vivo to characterize these cells. 
We previously described a genetic model where we inserted the cre-
recombinase (Cre) gene into exon 1 of the Pnmt gene [33] and when these mice were 
crossed with ROSA26-β-galactosidase reporter animals, β-galactosidase activity was 
specifically expressed in the medulla of the adult adrenal gland and in the developing 
embryonic heart in patterns consistent with those observed for endogenous Pnmt 
expression in those tissues [30, 31, 33]. However, this strategy has the limitation that 
both the active adrenergic cells and cells with adrenergic phenotype in the history have 
been marked at the same time, thus to distinguish those above cells is impossible. In 
order to fill this gap, in the second part of my thesis, we generate a new genetic model 
that the reporter gene can track the active adrenergic cells in animals. Our hypothesis is 
as the following: 
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Targeting of the Enhanced Green Fluorescent Protein Reporter to the regulatory 
elements of Pnmt genomic sequences to generate a new knock-in mouse model 
and this Pnmt-nEGFP model can efficiently mark the active adrenergic cells in 
both adrenal glands and other organs.  
We will set up two aims to test this hypothesis: 
1. Verification of this genetic targeting strategy and analysis of reporter gene 
expression in the adult adrenal gland. 
We will determine whether GFP positive cells could be found in the adult adrenal 
medulla and whether these expressions were tissue specific (only concentrated in 
medulla instead of cortex), whether these cells are adrenergic such as expressing Pnmt. 
In addition, if the above questions are answered, then we will further analyze the 
phenotypes of these GFP positive cells in adult adrenal glands. Questions needed to be 
answered include: 
Whether the GFP expression is localized in the nucleus or in the cellular part; 
Whether there’re any differences of GFP expression between homozygous and 
heterozygous animals.  
2. Determine whether the cells with GFP expression could be found in the mouse 
embryonic heart and if possible, further characterize these cells such as their 
location and dynamics of expression during development. 
For this aim, we will mainly use the immunohistochemistry to observe GFP 
expression from the sections of embryonic mouse hearts. If GFP signal is strong, 
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Fluorescence-Activated Cell Sorting (FACS) will be used for characterization and 
sorting of the positive cells. Pnmt-nEGFP pluripotent mouse embryonic Stem Cells 
(mESCC) will also be differentiated into cardiomyocytes and the expression of both 
Pnmt and GFP will be determined.  
Dependent on the sensitivity of Pnmt-nEGFP genetic animal model, the 
adrenergic cell populations during heart development [30, 31, 33, 34] could be 
characterized based on green fluorescence. However, the alternative strategies will also 
be generated if this genetic model can’t identify these transiently expressing cell 
populations. Considering the small number of these cells and other uncertainty of 
reporter gene expression based on GFP [35, 36], other strategies are created. The first 
alternative will be as follows: 
For Pnmt-Cre pluripotent mESC cells,  a dual fluorescence plasmid which 
includes both the coding sequence of red fluorescence protein (RFP) and GFP will be 
stably transfected, the whole RFP codons are conjugated with stop sequences and 
floxed by LoxP site on both ends [37]. Thus for this model, we will test the following 
aims: 
1. A Stable mESC cell line can be created which incorporate the dual fluorescence 
indicator, thus red fluorescence emission from cell clones after antibiotic 
screening.  
2. These positive clones can differentiate well into cardiomyocytes, and at some 
specific stages of cardic differentiation, portion of the cells, especially inside or 
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close to the beating loci will show fluorescence switch and green fluorescence 
could be detectable. 
For the second alternative, we will take the advantage of a powerful cell 
separation technology: Magnetic-Activated Cell Sorting (MACS) for the same purpose 
listed above. MACS is based on immunogenic reaction between magnetic beads and 
cell surface specific antibodies, which can be purified from the negative populations 
under the proper magnetic field [38]. It has been reported that mESC cells keep their 
self-renewal and diverse differentiation capabilities after sorting. In addition, the yield 
and the purity of the enrichment are very high compared with other methods [38-40]. 
Therefore, we will choose low-affinity nerve growth factor receptor (ΔLNGFR) as a 
surface marker to generate a new in vitro model to isolate and characterize the 
adrenergic cells during cardiac differentiation [41, 42]. The aims are as followings: 
1. Through a series of subclone procedures, generate the targeting construct which 
has ΔLNGFR as reporter gene. The construct is referred as Pnmt-ΔLNGFR-Neo-
DTA, which can knock in the ΔLNGFR cDNA into Pnmt genomic locus by 
homologous recombination. 
2. Generate the target mESC cell clones with the above targeting construct by 
electroporation into 7AC5EYFP pluripotent ES cells. Target cells are screened by 
antibiotics and biochemistry identification.  
Our long term goal is to efficiently enrich the cardiac adrenergic cell populations 
during fetal heart development determine the destinations of these cell, such as 
differentiation into various components of different chambers and conduction systems or 
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others such as apoptosis, and finally explore the exact functions of these cells, the 
mechanism of their function such as how they regulate the cardiac growth or adaption to 
hypoxic environment during this period. The electrophysiological properties of these 
cells will also help us identify their function. These information will greatly help 
researchers appreciate the detailed process of fetal heart development and provide 
useful clues for the cell regeneration therapies after myocardial infarction.  
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CHAPTER 2 : EVALUATION OF BIOLISTIC GENE TRANSFER 
METHODS IN VIVO USING NON-INVASIVE BIOLUMINESCENCE 
IMAGING TECHNIQUES 
 
2.1 Introduction 
 
Gene therapy is a promising strategy for correcting both genetic and acquired 
diseases [43, 44].  There are a variety of gene delivery methods currently available, with 
the main purpose of any given strategy being to efficiently transfer and express the 
target gene(s) of interest without adverse side-effects.  Development of improved gene 
delivery strategies is critical for application of effective gene therapies, yet evaluation of 
the effectiveness of these strategies is often hampered by difficulties in detecting 
transgene expression in real-time in vivo.  Non-invasive bioluminescent imaging (BLI) 
has been successfully used for evaluation of cell and gene therapies in small animal 
models [8, 10, 12, 45], though it has not yet been systematically applied to analysis of 
physical gene transfer methods.  The purpose of the present study is to evaluate the 
effectiveness of biolistic gene transfer in different types of tissue in mice using non-
invasive in vivo bioluminescence imaging (BLI). 
Vectors for gene delivery can be divided into two general categories: viral and 
non-viral.  Viral vectors are widely employed for gene therapy as they are highly efficient, 
and the effects can be sustained over periods of weeks, months, and sometimes years 
[1, 46].  A number of different viral vectors have been utilized for gene therapy 
approaches based on cell/tissue-type preferences.  Some of these include adeno- and 
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adeno-associated virus, herpes virus, retrovirus, and lentivirus, among others [47, 48].  
Each has its own advantages and disadvantages depending on application and tissue 
type.  In general, recombinant replication-defective (ie, crippled) viral vectors are used 
for this purpose to minimize threats of infection, immune responses, and other 
potentially adverse conditions.  In the past, serious consequences have resulted from 
the use of viral vectors for gene therapy in humans [9,10].  Most notably, the death of 
18-year old Jesse Gelsinger due to immune complications arising in response to 
adenovirus vectors essentially halted clinical trials using viral vectors for gene therapy 
for many years[49-51].  More recently, other viral vector-based gene therapy 
approaches have come into question because of associated genomic instability and 
activation of proto-oncogenes[52, 53].  Thus, it is becoming increasingly clear that there 
is an inherent risk of serious adverse side effects with some viral-based gene therapy 
strategies. 
Alternatively, non-viral gene therapy strategies pose less risk of infection and/or 
adverse immune responses.  Non-viral gene transfer techniques typically involve either 
chemical or physical methods.  Chemical methods such as calcium-phosphate or 
liposome-based approaches have achieved much success for in vitro applications in cell 
cultures, but have been of more limited utility in vivo due to low transfection efficiencies 
and toxicity issues[4, 54, 55].  Physical methods are diverse and include direct injection 
of DNA, electroporation, ultrasonic-based, and biolistic approaches in addition to a 
variety of other techniques.  In most cases where chemical or physical methods are 
employed, purified plasmid DNA is used for delivery.  When effective, this typically 
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results in transient expression in target tissues since the “naked” DNA is eventually 
degraded by host nucleases [6].  Thus, these methods are currently limited to specific 
applications where transient expression of a transgene is warranted (e.g., induction of 
angiogenesis) [56-59].   
In the present study, we chose to use physical methods of gene transfer to avoid 
complications associated with viral and chemical strategies.  In particular, we explore 
the use of biolistic methods of gene transfer due to its widespread applicability and low 
toxicity.  Biolistic gene transfer has been used for many years primarily for the study and 
production of transgenic plants [13-16].  It is, in fact, the preferred and most commonly 
used method for gene transfer in plants due to its versatility and effectiveness.  Due to 
their tough outer cell walls, plants typically require helium pressures well in excess of 
1000 pounds/square inch (psi), and the procedure is usually performed under vacuum 
using a stationary biolistic gene delivery chamber.  Animal cells, in contrast, cannot 
tolerate bombardment with such high pressure, nor are they amenable to vacuum 
conditions for the transfer process.  In recent years, however, a hand-held device 
known as the Helios™ gene gun (Bio-Rad Labs, Hercules, CA) has been developed for 
biolistic gene transfer experiments in animals using lower helium pressures (≤ 600 psi) 
[60].  No vacuum is required, and the DNA-gold particles can be delivered from a hand-
held gun that can be used to target virtually any tissue or organ for direct biolistic gene 
transfer.  This device has been used to successfully perform biolistic gene transfer in a 
number of mammalian cell-culture and live-animal models [17-19, 61, 62].   In the 
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current report, we use BLI to evaluate the effectiveness of gene transfer via biolistic 
techniques in vitro and in vivo.   
Cardiac gene therapy has passed a significant development period in the past 
ten to fifteen years as the advancement of molecular biology leading to both deep 
understanding the mechanisms of gene therapy and resulting in more experimental and 
therapeutical genes as candidates for gene therapy, at least in animal experimental 
models. In parallel, the development of new delivery methods which are designed to 
achieve higher therapeutic gene expression and less side effects also enriched the 
available technologies as different tissues and organs need different gene delivery 
strategies based on their specific biological properties. As we mentioned in the first 
section, vectors for gene therapy can be divided into non-viral and viral vectors. The 
viral vectors actually are the most focused strategies by researchers mainly because 
they own high transduction efficiency. Although the improving the performance of 
current viral vectors and discovery of new vectors never stops, there’re still serious 
concerns about their inner characteristics which include immunogenic responses, 
insertional mutations and proto-oncogene activation, just as we discussed in the first 
section. On the other side, the non-viral vectors have many advantages, their functional 
mechanisms are still yet fully uncovered. For some specific situations, non-viral vectors 
are even preferred concerned with its relatively shorter transgene expression, such as 
the induction of angiogenesis during heart failure.  
Previous views on naked DNA as a mean for cardiac gene therapy are mainly 
negative. Although the naked DNA can access to the target organs quickly, they’re not 
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easily penetrate to the target cells because 1) DNA are prone to degraded by DNAase, 
and 2) Without additional protective coverage to facilitate uptake, the entrance to cell 
membrane by negative charged DNA is limited. However, when considering the 
advantage of naked DNA, which includes but not limited to: low cost of production, very 
low immunogenic response and the following toxicity, heat stability and good solubility, it 
needs for further tested to best utilized from these advantages [63]. There is demanding 
need to further evaluate this method, especially direct naked DNA delivery to determine 
its effectiveness in vivo. Therefore, complementary technologies designed to assist 
naked DNA’s performance while reducing its defects are hot research fields. For 
myocardium gene delivery, which is often used for some purposes such as induction of 
angiogenesis and treatment of heart failure, many ways can be used to meet this 
requirement. Some researchers use catheter based direct injection [64]. Recently, DNA 
loaded microbubbles destruction in the heart by ultrasound is employed as a high 
efficient way to achieve transgene expression in the myocardium [65, 66]. However, 
direct injection into myocardium is still an efficient way for short term transgene 
expression, and is at least a good standard for comparison with other naked DNA 
delivery techniques. In this section, we use direct injection to the myocardium without 
thoracotomy with luciferase reporter plasmid and check the gene expression with non-
invasive bioluminescence imaging (BLI) and determine whether BLI can efficiently 
detect the dynamic changes of the transgene expression.  
Stem cells are promising strategies for treatment of severe cardiovascular 
diseases including heart failure, myocardial infarction and others. However, despite the 
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many multi-center clinical trials for the cell based therapies in cardiovascular disease, 
controversies about the outcome occurred and currently stem cell therapies haven’t 
been extended to large scale trials and practice. These results push both the basic 
scientists and clinicians to cooperate deeply to explore the mechanism of stem cell 
based therapies and discover new strategies for improvements [67, 68]. 
The most two difficult questions in this fields are actually mutual related, first one 
is what is the best ideal type of stem cell to be transplanted, and the second one is their 
behavior after engraftment in vivo[69]. Whether the cells are well retained and survival 
after transplantation, or dead, washed out through circulation systems, and the potential 
concomitant immunoresponse and toxicity such as teratoma formations are all important 
questions needed to be answered, and in realities these are intermingled and tough to 
figure out not just separately but comprehensively. 
Therefore, current situations prompt us to discover good technologies to monitor 
the post-transplanted cells. Cell imaging based strategies are then put the front line to 
meet this requirement and scientist hope to accurately localize and dynamically monitor 
stem cells in vivo[70]. Currently, several imaging modalities are paid more attention to 
track the stem cells very efficiently. They’re magnetic resonance imaging (MRI), reporter 
gene based imaging, including both radioactive probes and fluorescent proteins, and 
the derivative bioluminescent imaging (BLI). Each modality has its own strength in the 
application dependent on the specific purpose [70]. 
Embryonic stem (ES) cells are usually genetic manipulated in vitro for the 
following reasons. The genetic modification is utilized for lineage tracking and specific 
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phenotypes are desired with modification with respective gene, either by over-
expression or removal. The other reason is manipulated ES cells are helpful for in vivo 
detection by their tagged sequences. Reporter gene is widely used in the genetic 
modified ES cells as only live cells can actively launch the machinery transcription and 
translation of the reporter genes, thus allowing the cells could be identified, 
characterized and even sorted out[71, 72]. 
For application of reporter gene in ES cell identification, fluorescent protein gene 
is usually employed to form a target construct, in which these proteins are driven by the 
promoter from gene of interest. The most often used fluorescent proteins are GFP 
variants, spanned from wild type GFP to color shift family members CFP (Cyan) and 
YFP (Yellow). The respective genetic modified versions with higher brightness are also 
available, named as EGFP, ECFP and EYFP [73, 74]. These reporter genes extremely 
enriched the methodologies to investigate the specific types of ES cells, for their 
proliferation, differentiation, purification and in vivo performance tracing.  
The reporter genes can also utilize bioluminescence as an alternative way for 
quantitative comparison of ES cells [75]. Luciferase, which was initially discovered from 
fire fly which can convert the substrate luciferin to glowing luminescence. Thus Luc 
gene is engineered in the construct driven by specific promoter, and the regulation by 
the promoter can be determined from bioluminescent intensities provided the construct 
is inserted into somewhere in the ES genome. This is very helpful when we want to 
explore gene’s function in ES cells at different status and the therapeutic potential when 
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transplanted into experimental animals. In this section, a new type of ES cells, with Ncx-
1(Sodium-calcium exchanger-1) as the gene of interest, is characterized.  
 
2.2 Materials and Methods 
 
2.2.1 Evaluation of non-viral gene delivery 
The hand-held Helios Gene Gun, Tubing Prep Station, Optimization Kit (including 
gold microcarriers, polyvinylpyrrolidone or PVP, and tubing), and related supplies were 
obtained from Bio-Rad, Inc. (Hercules, CA). 
2.2.1.1 Reagents 
Human embryonic kidney (HEK) 293 cells and mouse embryonic stem cells were 
maintained as previously described [12, 76].  Cell culture reagents including Dulbecco’s 
Modified Eagle Medium (DMEM) and supplements were obtained from Invitrogen, Inc. 
(Carlsbad, CA).  Fetal bovine serum was purchased from Hyclone Labs (Logan, UT).  
Lipofectamine 2000 and XGAL were obtained from Invitrogen, Inc (Carlsbad, CA).  
Luciferin for in vivo use was obtained from Caliper Labs (Hopkinton, MA).  Bright-GloTM 
Luciferase Assay Kit for in vitro assays was supplied by Promega (Madison, WI).  All the 
other chemicals and  reagents used in this study were obtained from Sigma-Aldrich (St. 
Louis, MO). 
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2.2.1.2 Plasmids 
Plasmids used in this study included pCMV-LUC (Clontech, Menlo Park, CA) and 
pCMV-beta-galactosidase (pCMV-βGal) [77], pNCX1-LUC [78], have been described 
previously as indicated.  All plasmids were purified using Qiagen Maxi-Prep DNA 
purification kits (Valencia, CA) followed by phenol:chloroform:isoamyl alcholol (25:24:1) 
extraction, ethanol precipitation, 70% ethanol wash and air-drying.  The dried pDNAs 
were then resuspended in Tris-EDTA (TE, pH 8.0) buffer at a concentration of 1mg/ml.  
We found that the additional organic extraction and ethanol precipitation/washing steps 
were critical for achieving efficient coupling of pDNAs to gold microcarriers.  
2.2.1.3 Animals 
Adult white FVB mice (18-25g each) were used for this study.  The mice were 
housed in the Transgenic Animal Facility at the University of Central Florida (UCF) on a 
12:12hr light:dark cycle, and provided food and water ad libitum.  All procedures utilizing 
mice in this study were performed in accordance with approved UCF IACUC protocols 
consistent with NIH regulations governing vertebrate animal research. 
2.2.1.4 Preparation of gold microcarrier-coated cartridges 
Preparation of gold microcarrier-coated cartridges was performed according to 
the manufacturer’s instructions (Bio-Rad, Inc., Hercules, CA) as previously described 
[18, 60].  Briefly, 25 mg of gold microcarriers (1μm diameter average size) were 
suspended in absolute ethanol containing 0.05 M spermidine.  An equal volume of 
pDNA was added to this mixture, vortexed, and sonicated.  Various amounts of pDNA 
were used to evaluate different DNA-loading ratios (DLRs).  By definition, DLR of 1 = 
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1μg DNA per mg of gold microcarrier particles [60, 79].  An equal volume of 1M CaCl2 
was added to the mixture in dropwise fashion, and then precipitated at room 
temperature for 5 min (the volume of spermidine was always the same as those of 
plasmid and CaCl2). The solution was microcentrifuged (14,000xg) for 5s and the 
supernatant was removed.  The resulting pellets were resuspended with 100% ethanol 
and washed three times with same for 15s each.  Finally, the pellets were each 
resuspended in 2.5 ml absolute ethanol containing 0.05% polyvinylpyrrolidone (PVP), 
and sonicated to achieve uniform suspension of microcarrier particles prior to cartridge 
loading.  Cartridge tubing was loaded into the Bio-Rad Tubing Prep Station, dried with 
nitrogen gas, and coated internally with the microcarrier suspension during continuous 
rotation of the tubing.  After complete drying, the tubing was cut into 0.5 inch cartridge 
“bullets” using the supplied tubing cutter, and stored in the parafilm-sealed containers at 
4ºC until ready for use. 
2.2.1.5 Electrophoresis of microcarrier mixtures 
Just before the last centrifugation step to concentrate the microcarriers in absolute 
ethanol (see preceding paragraph), a portion of the suspension was transferred to 
microcentrifuge tubes, and dried in a Speed-Vac centrifuge (Savant Instrument Inc, 
Farmingdale, NY).  The pellet was resuspended in electrophoresis loading buffer and 
immediately subjected to electrophoresis in 0.8% agarose gels containing 0.2μg/ml 
ethidium bromide.  Each well was loaded with approximately equal amounts of 
microcarriers.  The gels were imaged under ultraviolet light. 
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2.2.1.6 In vitro gene delivery 
For biolistic delivery of reporter genes, cells were trypsinized and transferred to six 
well plates and kept until 80% confluence prior to gene transfer. Immediately before 
transfection, the medium was gently removed and washed once with PBS, the barrel 
ring of hand held gene gun was centered at the well and the distance to the cells was 
about 2 cm.  Upon pulling the trigger, the gold microcarriers were shot out of the 
cartridges by helium with pressures between 100-150 psi (1psi= 6.89 kPa).  Fresh 
growth media was added to the dishes and the cells were recovered in the incubator for 
another 48h before bioluminescence measurement.  As a positive control, some wells 
were transfected in parallel using lipofectamine according to the manufacturer’s 
instructions (Invitrogen, Inc.; Carlsbad, CA).  
2.2.1.7 In vivo gene delivery  
Mouse skin and liver were chosen as the targets of bombardment for dynamic 
gene expression observation. Prior to the procedure, the mice were administered with 
2% isoflurane to achieve a surgical plane, and maintained as such using a nose-cone 
for continuous isoflurane delivery (in oxygen, flow speed = 1L/min).   The mice were 
placed in supine position on a surgical pad, and the abdominal hair was removed by 
Nair® hair-removal lotion.  For biolistic transfer to skin, the barrel ring of the Gene Gun 
was lightly touching the skin.  For biolistic transfer to liver, an abdominal incision was 
made to expose the organ, and the barrel of the Gene Gun was positioned directly 
above the target.  Following biolistic delivery, the incision was sutured, and the mice 
were administered buprenorphine (0.05 mg/kg) in the thigh muscle to help mediate pain 
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or discomfort associated with the procedure.  The mice were then removed from 
anesthesia, returned to their cages, and were ambulatory within a few minutes.   
To determine if differences of DLR could affect expression of biolistically-
transferred genes, the mice were divided into four groups with six mice per each group, 
and DLR was varied between 0, 4, 10 and 25. Helium pressure was set to 200 psi, and 
the microcarrier bombardment was targeted to abdominal skin.  In a subsequent series 
of experiments, the helium pressure was adjusted to 300-400 psi for biolistic delivery to 
mouse skin since the lower pressure (200 psi) was well-tolerated in the initial group.  
For biolistic transfer to soft tissue (liver), helium pressure was held at a maximum of 200 
psi to minimize tissue damage. 
2.2.1.8 Direct injection of plasmid DNA  into mouse beating heart and 
bioluminescence detection in vivo 
 
In this experiment, we injected purified pCMV-LUC plasmid into the left 
ventricular muscle tissue of the mouse beating heart as follows.  The initial preparation 
of the mouse, including anesthesia and depilation of the abdominal area, was similar to 
that described above for the biolistic gene transfer experiments in previous sections.  An 
abdominal incision was made on the left side just beneath the lower ribs to expose the 
diaphragm.  With the assistance of a small forceps to stretch the diaphragm gently, the 
beating heart became clearly visible.  We then injected the plasmid DNA solution into 
left ventricular muscle using a 1cc Tuberculin syringe (27gauge from BD).  Mice were 
divided into three groups: (i) control group (PBS only), (ii) 10µg pCMV-LUC, and (iii) 
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50µg pCMV-LUC.  Following injection, the incision was sutured and mice were given 
buprenorphine as described above. 
Since the second day after injection, mice are checked for their luminescence 
every day. The protocol is similar with those utilized for biolistic transfer to mouse liver 
in previous section. Mice are i.p. injected with 150mg/kg luciferin, then anesthetized with 
isofluane, placed supinely in the nosecone in the stage of IVIS-50® and height was 
adjusted for proper distance to the CCD in order for high quality pictures. Five minutes 
were set as the period of time for capture of bioluminescence.  
2.2.1.9 Bioluminescence imaging (BLI) 
For in vitro BLI, luciferase assays were performed as previously described [77] 
except that the results were quantified using an In Vivo Imaging System-50 (IVIS-50) 
from Caliper Labs (Hopkinton, MA).  For in vivo BLI assessment, mice were injected i.p. 
with D-luciferin potassium salts (Caliper Life Sciences, Hopkinton, MA) at a dosage of 
150mg/kg, and maintained for 5 min before imaging.  The mice were then anesthetized 
with 2% isoflurane and placed in the IVIS-50 chamber in supine position where they 
were maintained with isoflurane administered through nose-cone ports inside the 
chamber.  The chamber temperature was kept constant at 37oC throughout the 
procedure.  Light emission was collected for 5 min, and the intensity was represented 
as the number of photons per second/ cm2/ steradian for a designated “Region of 
Interest” or “ROI”.  A standard “ROI” template was used for each experiment so that 
direct comparison of different data sets could be readily managed.  Images were 
processed using IgoPro Living Image® software (Caliper Life Sciences, Hopkinton, MA). 
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2.2.1.10 XGAL histological staining 
Following biolistic transfer of pCMV-βGAL to mouse skin as described above, 
mice were sacrificed three days later by decapitation while under full anesthesia (2% 
isoflurane).  The abdominal skin surrounding the biolistic target area (22 mm diameter) 
was excised and fixed with 4% paraformaldehyde for 1-2 hrs on ice.  The tissue was 
then transferred to a solution of 30% sucrose in PBS and kept at 4℃ overnight.  The 
skin was sectioned transversely (14μm/section) using a cryostat instrument. The 
protocol for the XGAL staining with acidified eosin counterstaining was performed as 
described previously [33].  
2.2.2 Characterization of ES cells transfected with luminescence reporter gene 
by BLI 
 
pNcx-1 is kindly from Donald Menick, [78], pMC1-Neo is from our lab [33], the latter 
is a neomycin cassette plasmid. The Bright Glow Luciferase assay kit is provided by 
Promega and described as in the first section of this chapter. 
2.2.2.1 Cell culture 
7AC5-EYFP from ATCC are derivative of mouse R1 ES cell line, both are germline 
competent. All the protocols related to ES cell culture are in accordance with guideline 
of ATCC and are detailed in Chapter Two, the main bulk of this thesis. 
2.2.2.2 Screening and Characterization of positive clones by BLI 
Cells were cotransfected with pNcx-1 and pMC-1 neo by electroporation. G418 
(Geneticin, In vitrogen) were added on the second day after trasnfection at 350μg/ml. 
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Around 10days after electroporation, colonies were picked up and transferred to 48 well 
plates covered with Mitomycin treated mouse embryonic fibroblasts (MEF). Drugs were 
included during the whole selection process. Cell clones are compared for their 
luciferase activity by BLI with IVIS-50® after lysed by Glo-lysis Buffer, also provided by 
Promega. Cells were through two round screening until 2-3 stably transfectant and with 
highest bioluminescence came out. One of the clones was chosen for all the following 
experiment. 
2.2.2.3 Correlation between the cell numbers of pluripotent Ncx-1 reporter mESC 
and bioluminescent intensities 
 
Different numbers of puripotent Ncx-1 cell clones were seeded into 24 well plates 
covered with gelatin. The number ranged from 0, 1000, 5000, 10,000, 50,000, 100,000, 
200,000, 50,000 and 1,000,000. 4hs after being seeded, after check the cells are 
completely attached, their Luciferase activities were determined through Bright-Glo 
Assay. Light production was measured by BLI and then confirmed with scintillation 
counting (Liquid Scintillation Analyzer, TRI-CARB2900TR, Packard). Standard curve 
was made to represent the correlation between cell number sand their respective 
Luciferase activities.  
2.2.3 Statistical Analysis 
Results are expressed mean values ± standard deviation.  One-way analysis of 
variance was used to determine if statistically significant differences occurred, with p < 
0.05 required to reject the null hypothesis. 
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2.3 Results 
 
Our initial experiments were designed to test the functionality of the biolistic gene transfer 
with BLI methods.  To accomplish this, we bombarded two different cell types in culture with 
gold (Au) particles coated with or without LUC reporter plasmid DNAs driven by different 
promoters.  As shown in Fig. 1A, HEK cells blasted with gold particles coated with pCMV-LUC 
produced a strong bioluminescent signal in the presence of the luciferin substrate.  In contrast, 
cells blasted with gold particles alone (Au) or coated with LUC reporter plasmids driven by the 
cellular promoter from the sodium-calcium exchanger 1 (NCX1) gene generated no measurable 
bioluminescent signal.  In parallel, we performed an analogous transfection experiment using an 
established in vitro transfection method using lipofectamine [80].  The results were similar to 
those achieved with the biolistic method except that CMV-LUC activity was much more robust in 
the lipofectamine sample compared with the biolistic sample in HEK cells.  In contrast, biolistic 
gene transfection produced brighter bioluminescence than lipofectamine for CMV-LUC in mESC  
(Fig. 1 C and D).  The pNCX1-LUC construct did not produce measurable bioluminescence 
when transfected by either method, and thus was not explored further in this study.     
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Figure 2-1. Luciferase expression in transfected cells in culture. 
(A&C)  HEK 293 and (B&D) mouse ES cells transfected using either lipofectamine 2000 
(A&B) or the Helios Gene Gun (C&D).  The top row in all sets of plates shown did not 
receive the luciferin substrate whereas it was provided to all wells in the bottom row of 
each plate shown.  The leftmost column of each plate contained mock-transfected cells.  
The middle column was transfected with pNcx1-LUC, and the rightmost column of each 
plate was transfected with pCMV-LUC. 
 
To perform biolistic transfer of LUC reporter plasmid DNA in vivo, we next evaluated the 
effectiveness of physical coupling of plasmid DNA to gold microcarrier particles.  The gold 
microcarriers were 1μm in diameter, on average, and increasing DNA loading ratios (DLRs) 
were evaluated by agarose gel electrophoresis. As shown in Fig. 2A, increasing the amount of 
pCMV-LUC in the coupling reactions led to greater retardation of the plasmid through the gel, 
thereby indicating that more of the plasmid DNA was being coupled to the microcarriers.  As the 
DLR increased from 4 to 10 or 25, however, increased amounts of uncoupled plasmid were 
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observed (“supercoiled” and “relaxed” bands, arrows, Fig. 2A), possibly indicating that some 
saturation of binding had occurred.  When the DLR was increased from 10 to 25, most of the 
plasmid did not enter the gel presumably because higher order DNA-gold coupling had occurred 
such that the complexes were now too large to enter the gel.  Less of the “free” supercoiled and 
relaxed plasmid DNA was present with a DLR of 25 compared to that observed with a DLR of 
10.  Macroscopic inspection revealed some “clumping” of gold particles at the highest DLR of 25, 
which is consistent with the idea that higher order coupling likely occurred in this group.   
To evaluate the efficacy of these different DLRs for biolistic gene transfer, we employed 
the Helios gene gun to deliver the gold microcarriers into mouse skin in vivo.  Reporter gene 
expression from the pCMV-LUC vector was then measured using BLI.  Quantitative analyses of 
these results are shown in Fig. 2B.  Expression appeared highest 24h after biolistic delivery, 
and then declined steadily over the next few days.  Surprisingly little difference was observed 
with the different DLRs.  Representative images of in vivo BLI for mice in these experiments are 
shown in Fig. 2, panels C-F.  In the absence of plasmid DNA, no BLI was apparent (DLR = 0, 
Fig. 2C).  In contrast, the BLI results for panels D-F (Fig. 2) showed similar levels of 
bioluminescence activity under the conditions used for these experiments.  No significant 
differences in bioluminescence were seen using microcarriers with DLRs = 4, 10, and 25 
(p≥0.05), though there was a trend towards increased bioluminescence with increasing DLR 
after day one.   
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Figure 2-2. Evaluation of DNA-Loading ratio (DLR). 
Picture of ethidium bromide-stained agarose gel showing plasmid DNA-gold 
microcarrier coupling.  The amount of microcarriers calculated to contain 100 ng of 
plasmid DNA was loaded per lane.  Lanes: M, marker (1 Kb ladder; P, plasmid DNA 
(pCMV-LUC) alone; 0, 4, 10, 25 refer to DLRs for the respective lanes indicated.  (B) 
Luciferase activity in mouse skin following biolistic transfer of pCMV-LUC at different 
DLRs.  BLI was performed daily for four days after gene delivery (n=6). (C-F) 
Representative pictures from different DLRs one day after biolistic gene transfer.  
 
To maximize gene transfer effectiveness and consistency, we chose the middle DLR of 
10 to compare the efficacy of biolistic gene transfer into different tissue types in vivo.  In this 
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series of experiments we used BLI to measure reporter gene activity following biolistic transfer 
into either superficial (skin) or internal (liver) tissue in vivo, as shown in Fig. 3.  Peak BLI activity 
was observed at the 2d time-point following biolistic gene delivery into both tissues, with skin 
showing much greater BLI activity than liver at this point.  Over time, however, BLI activity in 
liver was sustained much longer than that seen in skin.  For example, relatively strong BLI 
activity persisted through 8d after gene transfer into liver, whereas BLI activity in skin was nearly 
undetectable by the 8d time-point.  BLI activity remained relatively stable in the liver between 4-
8d following gene transfer, and then began to steadily decline over the next week (Fig. 3G).  
The last time-point measured in these experiments was 13d post-delivery, and there was still a 
small but measurable amount of BLI activity present in the liver group.  These results show that 
while biolistic gene transfer was effective for both liver and skin, the dynamic features of 
reporter gene expression in these two different tissues varied over time. 
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Figure 2-3. Comparison of BLI following biolistic reporter gene transfer into mouse liver 
or skin. 
Representative mice are shown at day 2 (A and D), 4 (B and E) and 8 for (C and F) 
following biolistic gene transfer. Pictures in A through C are for liver and those in D 
through F for skin. In each panel, the mouse on the left was transfected with gold 
microcarriers alone, and the mouse on the right was transfected with gold microcarriers 
conjugated with pCMV-LUC (DLR=10).  Quantitative assessment of these data is shown 
in panel G. 
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To determine the depth of gold microcarrier penetration following bombardment of 
mouse tissue, we performed histological assessments of abdominal skin 3d following biolistic 
gene transfer.  In these experiments, we used pCMV-βGAL reporter plasmid (DLR = 10) to 
facilitate observation of reporter gene activity in histological sections.  The gold microcarriers 
were readily observed in histological sections (Fig. 4, arrows).  Many of them were found in the 
outermost layer of skin (epidermis), but there were clearly clusters of these particles found in 
deeper layers.  Most of these particles were found approximately 100μm from the surface of the 
skin, though some were observed as deep as 200-300μm from the surface.  In contrast, reporter 
gene activity, as visualized by blue XGAL staining, was mainly found near the surface of skin, 
though patches of cells expressing βGAL were seen as deep as ~150μm from the skin surface 
(Fig. 4, arrowheads).  These results indicate that biolistic gene transfer was effective at or near 
the tissue surface under the conditions employed in these experiments. 
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Figure 2-4. Identification of transfected cells in vivo following biolistic delivery of gold-
coupled pCMV-βGal into mouse skin.   
(A-C)  Low-magnification (20X objective; scale bar, 100 μm) and (D-F) Higher-
magnification (40X objective; scale bar, 60 μm) views of transverse sections of mouse 
skin collected three days after biolistic gene transfer.  The sections were stained with 
XGAL (blue) and eosin (pink).  Examples of microcarriers are indicated by arrows, and 
transfected cells were identified by blue XGAL staining (arrowheads).  
 
To determine if BLI could effectively monitor cardiac gene expression in vivo, we 
injected pCMV-LUC plasmid DNA directly into the left ventricular muscle of the beating 
heart.  BLI activity was then assessed over a 10d period following injection.  
Representative mice from these experiments are shown in Fig. 5, where it can be seen 
that peak BLI activity was observed ~3d after injection of 50μg of pCMV-LUC.  BLI 
activity then decreased steadily over the next week until it became undetectable by 10d.  
In one set of experiments, we also tried 10μg of pCMV-LUC per injection.  BLI activity 
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was observed over a similar time-course as that observed for the 50μg injections, 
though the intensity of the activity was substantially less than that observed when we 
used 50μg of pCMV-LUC (not shown).  In both cases, BLI activity first appeared 2d after 
the injection.  These results demonstrate that BLI can serve as a useful monitor of 
reporter gene expression in the heart as well as in the liver or skin.  Thus, BLI can be 
used as an effective non-invasive tool for evaluating the effectiveness of gene transfer 
in vivo using a variety of delivery strategies. 
 
 
Figure 2-5. BLI of adult mice following direct injection of pCMV-LUC into ventricular 
myocardium. 
Mice were imaged at days 2, 3, 6, and 10 (panels A-D, respectively) post-injection with 
50 μg pCMV-LUC.  A control mouse that received only vehicle (PBS) injection is shown 
on the left side of panel A.  No BLI activity was observed from vehicle-injected controls 
at any of the time-points evaluated. 
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We initially picked up 144 positive clones after electroporation with Ncx-1 and 
MC1-Neo plasmid together. Not all the clones survived even after pick up, some of them 
are dead, some of them didn’t show convincing Luc activities. Thus after first round 
selection with G418, there’re around 20 clones left for secondary screening, and till the 
end of this drug selection and Luc activity measurement, there’re three clones left for 
further identification. Finally, Ncx-43 was chosen as candidate for the next following in 
vitro and in vivo experiments because after in vitro differentiation into cardiomyocytes 
the baseline Luc activity increased around 2.5 folds.  
The correlation of the input cell numbers and their accumulated luminescence 
were shown in Fig.6. Basically, the quantified luminescence faithfully correlates with the 
respective pluripotent ES cell numbers, that just confirms within specific window (higher 
than threshold but lower than saturation level), BLI is a reliable tool for quantification of 
population of same cells. On the other hand, it also indicates the cloned cells are stable 
transfectant, instead of mixed population with both trasnfected and untransfected cells, 
and it is mostly possible that cells in the population have been inserted with even copies 
of reporter gene. Combined with other data that the transcript level (mRNA) also 
faithfully correlates with luminescence, the total data suggest the basic characteristics of 
this engineered reporter ES cells includes nearly even copy insertion and stable 
incorporation into single cells. These reporter cells provide a new potential for 
therapeutic applications in myocardial infarction model.  
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Figure 2-6. Standard curves showing the relationship between BLI and pluripotent Ncx-
1 mESC number.  
(A) Schematic illustration of the Ncx-1-LUC construct used to transfect mESC. (B) Pluripotent 
Ncx-1 -43LUC cells were seeded into 24-well Petri dishes at various concentrations per well (in 
1 mL of culture medium): 0, 1,000, 10,000, 50,000, 100,000, 200,000, 500,000, and 1,000,000 
cells. The cells were allowed to settle and attach over a 4-h incubation period. They were then 
evaluated for LUC activity using the Promega Bright-Glo Assay. Light production was measured 
by BLI using the IVIS, and confirmed using scintillation counting. (B) Standard curve for the 
high concentrations of cells. (C) Standard curve for the low concentrations of cells. 
 
 
2.4 Discussion 
 
In the present study, we have shown that different types of tissues display differential 
kinetics of transgene expression following physical gene transfer in vivo.  We evaluated biolistic 
gene transfer in external (skin) and internal (liver) tissue.  In each case, we were able to 
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effectively monitor and quantify reporter gene expression using BLI.  The main advantage of this 
approach is that expression of the gene transferred could be evaluated repeatedly in the same 
animals over a period of several days using non-invasive imaging (BLI) methods.  Thus, this 
strategy requires fewer animals, reduces variability inherent in comparing different animals, and 
is more economical both in terms of time and money compared with more traditional 
approaches for analysis of gene therapy methods because fewer tissue samples need to be 
processed for analysis.  Of the tissue types evaluated, decline in transgene expression was 
most rapid in the skin (3-4d) and most stable in the liver (10-14d).  Thus, the principal finding of 
this study is that transgene expression kinetics are highly tissue-dependent.      
Biolistic gene transfer methods are standard for plants, but relatively fewer studies have 
explored this method of gene transfer in animals.  One of the key parameters that we initially 
evaluated was the DLR, which represents the amount of DNA used for coupling to a set amount 
of gold microcarriers.  We analyzed various DLRs over a range recommended by the 
manufacturer of the Helios gene gun.  Despite clear differences in DNA-gold coupling as 
evidenced by our gel electrophoresis results, there was surprisingly little difference in transfer 
efficiency in vivo using DLRs of 4, 10, or 25 (Fig. 2).  A likely explanation for these results is that 
the gold microcarriers became saturated with bound plasmid DNA when DLRs of 4 or higher 
were used, though higher order complex formation resulting in clumping of the microcarriers 
was observed when DLR was raised to 25.  Such clumping can be problematic in that it makes 
it difficult to apply a uniform coating of the discharge cartridges, potentially leading to 
inconsistent results.  Hence, we chose the next highest DLR of 10 for our experiments to avoid 
this potential problem.  These findings are consistent with previous reports [18] and with 
preliminary studies in our laboratory where we found that DLRs of 2 or lower appeared to 
produce less reporter gene expression compared to DLRs of 4 or higher (not shown).  
Conversely, using DLRs greater than 10 is probably not recommended because most of the 
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DNA used will be uncoupled or bound up in higher order complexes resulting in clumping.  
Therefore, the optimal DLR appears to be in the range of 4-10 when using conditions employed 
in the present study. 
Helium pressures used in our study varied between 200-400 psi.  Although not 
systematically evaluated here, we found that pressures of 300-400 psi were well-tolerated in 
skin.  Other studies have used even higher pressures (500 psi and above) for biolistic-mediated 
gene “vaccinations” in skin and also observed relatively little tissue damage [62, 81, 82].  
Maximum recommended helium pressure for the Bio Rad Helios gene gun is 600 psi.  It is 
anticipated that “tough” tissues such as skin and muscle can tolerate pressures approaching 
this maximum, but that “soft” internal tissues may not.  Consequently, we used lower helium 
pressure (200 psi) for gene transfer to liver, which is similar to what was used in a previous 
study (250 psi) to deliver the DNA element regulating cytochrome P450 2B1[19, 83].  We were 
reluctant to try higher pressures in liver for fear of causing serious tissue damage, and there did 
not appear to be a need to do so anyway because expression in liver was fairly robust under the 
conditions utilized here.  In fact, expression persisted in liver for several days beyond that 
observed in the skin.  The reason for this observation is not clear, but may be due in part to 
relatively high turnover of epidermis and/or differential nuclease activities in the two tissues.  
Indeed, histological assessments revealed that most of the microcarriers were localized to the 
epidermis following biolistic transfer to skin, with a maximum penetration of not more than a few 
hundred microns representing approximately 20-30 cell layers from the surface even when 
employing the highest helium pressure (400 psi) used in this study.  Taken together, these 
results suggest that biolistic gene transfer conditions need to be optimized for each different 
type of tissue targeted. 
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As we mentioned in the introduction, various methods can introduce the naked 
DNA into the myocardium, however, direct injection is still the simplest way for transient 
transgene expression. In this experiment, we intended to choose injection through 
diaphragm through abdominal cavity instead of thoracotomy for following reasons: 1) 
Thoracotomy is a more tedious surgery process as it needs the chest open, thus we 
must use respirator to assist the breath of animal as the thoracic cavity is deflated in this 
procedure. The surgery itself is risky which sometime can lead to the death of animals. 
2) Even under the chest open situation, the fast moving heart is still a challenge for 
needle position and injection, on the other hand, through the diaphragm, we can still see 
the heart very clearly, and with multiple preliminary practices we can well control the 
depth we push forward to the beating heart, thus achieving similar outcome brought by 
open chest injection. 3) We will make sure the injection is at right place after the whole 
bioluminescence measurement is finished by post-mortem inspection. The needle track 
is carefully checked, and we find consistent correlation between bioluminescent 
intensities and correct needle track, some animals not injected properly also have poor 
luminescence. 
For this type of experiments, we initially design to deliver the transgene to larger 
animals such as rat and rabbit, as previous reports showed that biolistic delivery to 
beating heart [17, 84] is feasible and transfected reporter gene can be found efficiently. 
However, this was not doable for small tissues and organ targeting, especially for 
mouse heart, with configuration of the current available gene gun from Bio-rad. 
Although a similar strategy which treated donor rat heart of antisense for particular gene 
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by high pressure to the recipient rat can reduce the acute cardiac rejection, direct gene 
delivery to heart of small animals are not reasonable currently.   
Consequently, we switched to more classical DNA injection methods for reporter 
gene delivery to mouse ventricular muscle.  Again, BLI proved to be effective at 
monitoring gene expression even through the closed chest for up to 8 days or so 
following the initial transfer.  A previous study did successfully use biolistic methods to 
transfer a reporter gene into beating rat hearts [17], which was somewhat more feasible 
than trying to do similar in mouse hearts because of the larger size of the rat model.   
In addition, similar experiments have been done before which luciferse were also 
determined [6, 7, 85]. However, beside the difference of gene delivery by thoracotomy, 
these previous reports have to sacrifice the target animals at different time points, and 
then extract the tissues for in vitro luciferase assay. In contrast, we employed non-
invasive BLI to measure reporter gene activity in vivo, which reduced the need for 
animal sacrifice and obviated the necessity of tissue extraction typically employed in 
these types of investigations.  The animals’ individual susceptibility is also reduced to 
minimal levels as single animal was continuously monitored instead of different animals 
used at various time points in previous studies[6, 7].  
The success of bioluminescence detection with CMV promoter is encouraging for 
future directions to use mammalian reporter gene into beating myocardium. These are 
our future plans and we hope to cover more mammalian promoter driven luciferase 
construct. These include E2F, β-actin, ubiquitin, CA promoter (chicken β-actin promoter 
with CMV enhancer) and others. The expression driven by mammalian vectors will test 
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the feasibility of this method more convincingly. Eventually, we will use cardiac specific 
promoter for application to myocardium gene delivery, such as α-MHC (α-Myosin heavy 
chain), MLC-γ (Myosin light chain γ) and others. If still functional, this is a very efficient 
way to deliver non-viral exogenous gene construct into beating heart of experimental 
animals. 
In the second part of this chapter, my colleagues and I established a new 
reporter mESC line with Ncx-1 and MC1-Neo plasmid stably transfected into pluripotent 
EYFP mESCs. Serial experiments show that Ncx-1, an early cardiac development 
marker from feline can successfully drive the luciferase reporter gene expression and 
this expression is further increased after differentiation into cardiomyocytes. In addition, 
these differentiated cells well incorporate into the neonatal hearts after direct injection 
through chest wall. Histology analysis confirmed some, although not many of the 
transplanted cells wereed positive for cardiomycyte marker sacromeric α-actinin. Thus, 
we confirm molecular imaging based on BLI as a useful tool to systemically screen 
engineered mESC line by random insertion of reporter genes both in vitro and in vivo. If 
promoter is properly chosen, it is a good tool to explore the mechanisms of 
cardiogenesis from this simple model as we can analyze the mechanism of different 
status, such as differentiation , survival and final cell fate, and the cells can be tracked 
for their behavior after engraft in vivo. In addition, specific cell lineage can be quantified 
and sorted based on the reporter gene or combined with other lineage markers. Overall, 
this is a useful model and the preliminary data we obtained did show optimistic potential 
that Ncx-1 ES cells as a good candidate for cell therapy in the experimental myocardial 
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infarction model and further experiments are under investigations.  Other groups also 
use BLI strategies to engineer mouse and human stem cells [10, 86, 87], and the results 
are similar with ours which clearly shows the advantage of BLI during this application. 
 
2.5 Limitations and Future Directions 
 
This investigation was limited to two target tissues in vivo: skin and liver.  To compare 
expression from biolistic-delivered reporter genes, we shot the same CMV-LUC gold “bullets” 
into these tissues and compared the resulting responses over time in vivo using BLI.  An 
advantage of using the CMV-LUC reporter is that it produces strong LUC activity that is readily 
measured using BLI.  This appears to work particularly well for short-term transient expression, 
and is consistent with earlier work showing that this promoter is strongly expressed in mouse 
liver following transfection in vivo [88].  On the other hand, the CMV promoter/enhancer has 
limited and questionable utility for longer-term sustained transgene expression applications.  
Even though we did not use a viral vector, the presence of the strong viral enhancer/promoter is 
still a potential concern.  It is well known, for example, that CMV and other strong viral promoter 
are typically silenced by host methylation mechanisms once they integrate into genomic DNA 
[89, 90].  The site of integration can also be problematic in some cases such as those where 
nearby proto-oncogenes get activated as a result [14,15].  Future studies will be developed to 
investigate tissue-specific promoters tailored to the relevant target tissues.  The present study 
focused on short-term transient expression, but future studies could evaluate more sustained 
expression over time for various gene therapy strategies.  The use of homologous human 
sequences and tissue-specific non-viral enhancer/promoter elements could be directly applied 
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using biolistic approaches.  BLI should prove useful for continued evaluation of these 
approaches in near real-time in vivo. 
Despite the wide application of non-viral vectors in gene therapy, non-viral 
vectors still have lots of disadvantages. Low trasnfection efficiency overall hampers the 
utilization of this method in conditions in which longer gene expressions are expected. 
The decline dynamics of transgene in vivo is poorly controllable due to complex 
degradation systems compared with viral vector systems. Therefore, the application is 
still limited to short term gene expression and viral vectors are still the best choice for 
long term purposes. 
The second shortcoming is we use CMV promoter reporter gene, which some 
time can lead to gene silencing from methylation of promoter sequences. Thus 
sometime it will be difficult for comparison of transfection efficiency with multiple delivery 
strategies. 
The method of plasmid administration also has limitations. As through the 
diaphragm although the beating heart is visible, but practically it needs exquisite 
techniques to push forward the needle to the ventricles, the master of this techniques 
takes some time and not always well learned. In addition, the mouse heart close to the 
diaphragm is mainly composed of right ventricles, where the myocardium walls are less 
thinner than left ventricles, so injection through this side makes heart more vulnerable 
for ruptures which leads to more difficulties and insistences in real operations.  
For the experiments in the second part of this chapter, there’re also some 
limitations. First, the Ncx-1 transfection is based on random genome integration of the 
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reporter gene. Although we established this stable mESC line, we didn’t specifically 
determine where this construct was inserted in the genome. We can only estimate each 
cell incorporates similar copies of construct, but the detailed information is lacking. As 
we know, sometimes, the transgene is inserted into the chromosome with pact gene 
sequences, therefore, the target genes are difficult for transcription as the transcription 
factor can’t easily access to them. The random insertion sometimes results in unknown 
genetic processes such as silencing of exogenous gene expression. We used another 
plasmid (α-MHC) for the same purpose in the studies, and the results were beyond 
expectations as luminescence activities were decreased after cardiac differentiation. 
The different performances after cardiac differentiation among various promoters might 
come from the discrepancies of promoters, although α-MHC promoter contains the key 
elements for myocyte development [91], the relative short size (353bp) of this promoter 
could limit its function to control the transcription of reporter gene, especially after 
induction of cardiac differentiation. 
Alternatively, to minimize the potential imbalanced expression of the targeted 
construct for the generation of reporter mESC, we can use one targeting construct 
instead of two (Ncx-1 and MC1-Neo) hereof. The promoter of this neomycin cassette is 
derived from β-actin which is ubiquitously expressed. Although the expression of 
neomycin resistance gene should be similar compared with Ncx-1 luciferase as same 
dosage used during electroporation, however, the significant differences among the 
ESC clones concerned with their luminescence indicate that the imbalanced expression 
of the two constructs may exist. Therefore, if the cDNA of neomycin resistance gene is 
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inserted into the Ncx-1 construct, then both the antibiotic resistance and luciferase 
expression are under regulation of the same promoter, thus hypo- or hyper activation of 
Ncx-1 will be reduced to minimal levels, and the performance of the selected clones will 
be less divergent and results will be more consistent.  
 
2.6 Conclusions 
 
We have shown that biolistic gene transfer can be efficiently optimized in 
different tissues using non-invasive BLI to monitor expression in the same animals 
repeatedly over time in vivo.  Of the representative tissue types evaluated, expression 
peaked within 2-3 days for both, but declined most rapidly in the skin (3-4 days) 
compared to liver (10-14 days).  Thus, tissue-specific expression kinetics should be an 
important consideration in the design of effective gene therapies using physical gene 
transfer techniques, which may serve as potentially useful gene delivery strategies 
compared with existing viral-based approaches.  Biolistic gene transfer methods appear 
to offer an attractive, safe, and effective alternative to viral vectors for gene therapeutic 
strategies that can be directly applied in the clinic to treat a wide variety of human 
ailments.  So far, biolistic gene transfer applications in the clinical setting have been 
primarily focused on transfection of cells in culture which are then transplanted to the 
patient [23, 92-94].  A more recent study [21] directly targeted external tissues such as 
epidermis for vaccination applications, and it is anticipated that there will be more of 
these types of applications developing for biolistic gene transfer in the future.  The BLI-
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based assessment strategy described here should facilitate optimization of biolistic 
conditions for different tissue types in the pre-clinical setting, thereby providing an 
efficient means of pre-evaluation of in vivo efficacy in animal models prior to human 
trials.  In the same time, the BLI is also successfully applied for detection of transgene 
expression in normal animals by other non-viral gene delivery methods, such as naked 
plasmid injection into the mouse beating hearts. BLI is also an efficient tool to evaluate 
the function of mouse mESC cells targeted with cardiac specific reporter gene, the 
difference of bioluminescent activities between pluripotent and cardiac differentiated ES 
cells. In addition, only cardiac differentiated mESC can result in maintenance of 
bioluminescence after transplantation in neonatal hearts which shows BLI is a good 
modality for assisting studies of mechanisms of differentiation during development.  
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CHAPTER 3 : TARGETING OF THE ENHANCED GREEN 
FLUORESCENT PROTEIN REPORTER TO ADRENERGIC CELLS IN 
MICE 
 
3.1 Introduction 
 
Adrenergic hormones are key molecular modulators of physiological stress 
responses and are essential for heart function during fetal and early neonatal 
development [24, 95, 96].  The principle adrenergic hormones in mammals are 
adrenaline and noradrenaline.  In adults, they are primarily produced in the chromaffin 
cells of the adrenal medullae where they can then be secreted directly into the 
bloodstream during periods of stress [24].  In the developing embryo, however, the 
major site of production first occurs in the heart [30-32].  In fact, mouse gene ablation 
studies have demonstrated that this period of expression in the embryonic heart 
corresponds with the only developmental stage where adrenergic hormones are 
absolultely essential for animal viability  [96]. 
In addition, adrenergic hormones are produced by neurons in the central and 
peripheral nervous systems and also by several other cell types including  lymphocytes 
and cells in the retina, kidney, spleen, and testes [25, 27-29, 97, 98].  However, the role 
of adrenergic hormones in these non-neuronal tissues is at present poorly understood. 
 Adrenergic cells can be identified by expression of the biosynthetic enzymes 
responsible for production of adrenaline and noradrenaline.  Dopamine β-hydroxylase 
(Dbh) converts dopamine to noradrenaline, and phenylethanolamine n-
46 
 
methyltransferase (Pnmt) converts noradrenaline to adrenaline.  Thus, Pnmt expression 
generally serves as marker for adrenaline-producing cells while Dbh expression in the 
absence of Pnmt expression generally serves as a marker for noradrenaline-producing 
cells.  Using targeted genetic strategies in mice, we previously described a model where 
we inserted the cre-recombinase (Cre) gene into exon 1 of the Pnmt gene [33].  By 
inter-breeding these mice with ROSA26- β-galactosidase reporter animals, we showed 
that the β-galactosidase reporter was specifically expressed in the medullae of the 
adult adrenal gland and in the developing embryonic heart in patterns consistent with 
those observed for endogenous Pnmt expression in those tissues [30, 31, 33].  The 
Cre/ROSA strategy marks cells that actively express Pnmt as well as those that had a 
history of expressing it sometime earlier in development, thereby identifying all the cells 
within a tissue that are derived from an adrenergic lineage.  A limitation of this approach, 
however, is that it is impossible to distinguish cells that are actively adrenergic versus 
those that are not now  synthesizing hormones but are descendants of precursor cells 
that were adrenergic. 
To overcome this limitation, we developed a new model by targeting a nuclear-
localized Enhanced Green Fluorescent Protein (nEGFP) gene to the mouse Pnmt locus 
to create Pnmt-nEGFP reporter mice.  The present study describes the initial 
characterization of these mice, including verification of genetic targeting and analysis of 
reporter gene expression in the adult adrenal gland and developing heart.  We also 
characterize the activation of GFP expression and of endogenous Pnmt in mouse 
embryonic stem cells as they differentiate into beading cardiomyocytes. The results 
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show that the nEGFP reporter gene appears to be exclusively expressed in adrenergic 
cells and thus may serve as a useful model for identifying, isolating, and characterizing 
viable adrenergic cells from a variety of tissues and developmental stages.     
  
3.2 Materials and Methods 
 
3.2.1 Materials 
Andwin Scientific Tissue-Tek* CRYO-OCT Compound was obtained from Fisher 
Scientific (Pittsburgh, PA).  Sheep anti-Pnmt primary antibody was from Chemicon, Inc. 
(now Millipore).  Texas-Red conjugated anti-sheep IgG secondary antibody was 
obtained from Jackson Immunoresearch (West-Grove, PA).  Vectashield® mounting 
medium for fluorescence (H-1000) and mounting medium with Propidium Iodide (H-
1300) were obtained from Vector Laboratories (Burlingame, CA).  Cell culture media 
(Dulbecco's Modified Eagle Medium) and supplements were from Invitrogen (Carlsbad, 
CA).  Fetal bovine serum was from Hyclone (Logan, UT).  TRIzol® and MuLV Reverse 
Transcriptase were also from Invitrogen.  All other chemicals and reagents used in this 
study were obtained from Sigma-Aldrich (St. Louis, MO). 
3.2.2 Pnmt-EGFP construct 
The mutagenesis construct was generated essentially as described [8] but 
replacing the Cre recombinase gene with the cDNA for Enhanced Green Fluorescence 
Protein (EGFP) tagged with nuclear leading sequence (nEGFP). Thus this construct 
48 
 
fuses Pnmt 5’ non-coding sequences and the Pnmt ATG to sequences encoding EGFP.  
A frt-flanked neomycin cassette was inserted behind EGFP for positive selection. The 
Diphtheria toxin A (DT-A) cassette was placed outside of the homologous arms as a 
negative selection marker.  The linearized Pnmt-EGFP plasmid was electroporated into 
R1 mouse embryonic stem cell (ESC) line and G418 resistant clones were isolated and 
their DNAs were analyzed by Southern blotting using probes external to the targeting 
construct. The correct targeted ESC lines were injected into blastocysts of mouse 
embryos.  Chimeric founder animals were crossed with Jackson Laboratories strain 
003946.  These animals are transgenic for the FLP1 recombinase gene [10], thus 
allowing us to remove the NeoR cassette. Subsequently, mice were backcrossed and 
maintained in a 129X1/SvJ genetic background.   Genotyping was accomplished by 
PCR using a three primer system (5’-CAGGCGCCTCATCCCTCAGCAGCC-3’; 5’-Pnmt-
CTGGCCAGCGTCGGAGTCAGGGTC-3’; 5’-GCTCGACCAGGATGGGCACC-3’) to 
identify bands of 200 and 181 base pairs specific for the wild-type Pnmt and the 
Pnmt::GFP insertion alleles, respectively. 
3.2.3 Fluorescence and immunofluorescence histology 
All animal work was done according to NIH and to PHS policy and was approved 
by the Animal Care and Use Committees of the NICHD and University of Central Florida. 
Embryos from wild type (Pnmt+/+), heterogeneous (Pnmt+/nEGFP), and homozygous 
mutant (PnmtnEGFP/nEGFP) were isolated and dissected at developmental stages 
described in text with noon of the day of the vaginal plug designated as embryonic day 
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0.5 (E0.5). The protocols for dissection and immunofluorescent staining are as 
described [33].  
3.2.4 Quantification of EGFP+ cells 
For adult adrenal gland, positive fluorescent cells were counted between 
heterozygous and homozygous strains. For this purpose, pictures were taken from 
adrenal gland sections using a 20x objective lens.  The exposure time and 
compensations were set same for all the samples in order for comparison and 
quantification. In order to exclude disturbance from autofluorescence, image under red 
fluorescence filter from each sample was also captured.  A cell with nuclear-localized 
green fluorescence without red fluorescence was designated as EGFP+.  Counting was 
performed by separate people who were blinded as to genotype of each sample. 
3.2.5 Differentiation of mES into beating cardiomyocytes 
Both R1 and Pnmt-nEGFP pluripotent mES cells were maintained on mouse 
embryonic fibroblasts in DMEM medium supplemented with 15% fetal bovine serum 
plus 1000units/ml Leukemia inhibitory factor (LIF or ESGRO®, Millipore). mES were 
differentiated by the hanging-drop as described previously [99].  
3.2.6 RT-PCR 
The total RNA of mES cells at different differentiation stage were extracted by 
TRIzol® reagent, and cDNA were synthesized with MuLV Reverse Transcriptase. RT-
PCR was processed for analysis of Pnmt mRNA expression with the following primers: 
forward: 5’-GGTGGCTCAGACCTGAAG-3’ and reverse: 5’-
GCCATCAGGGTTGCTCAG-3’. The PCR product was detected under agarose gel 
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electrophoresis.  RNA from adult adrenal glands was used as a positive control for Pnmt 
expression, while absence of input RNA was used as a negative control. 
3.2.7 Statistic Analysis 
For the quantification of EGFP-positive cells from adrenal glands, the average 
from five samples of each genotype was calculated and expressed as Mean±S.E.M.  
Student t-test was used for comparison between heterozygous and homozygous group, 
with p < 0.05 required to reject the null hypothesis. 
 
3.3 Results 
 
3.3.1 Genetic targeting of the nEGFP reporter gene to the Pnmt 
To identify and evaluate adrenergic cells in vivo, we inserted the EGFP reporter 
gene with a nuclear localization sequence (nEGFP) into exon 1 of the endogenous 
mouse Pnmt gene as outlined in the schematic shown in Fig. 1A. Correct targeting was 
confirmed by Southern blotting (Fig. 1B) using 5’ and 3’ probes external to the genomic 
sequences used to direct the homologous recombination. A correctly targeted clone 
was used to make the knock-in mice.  Through successive breeding, we  removed the 
Flp flanked NeoR cassette and obtained Pnmt+/+,  Pnmt+/nEGFP , and PnmtnEGFP/nEGFP 
littermates for analysis. Note that even though the Pnmt insertion completely abrogates 
expression of Pnmt and thus eliminates adrenalin, PnmtnEGFP/nEGF animals are 
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viable, fertile, and show no obvious differences in health, weight, or appearance (data 
not shown).  Similar results were already reported for the Pnmt Cre/Cre animals [33] . 
 
Figure 3-1. Strategies for construction of Pnmt-GFP allele.  
A. Skematic depiction of wild type (i), Pnmt-GFP-Neo (ii) and Pnmt-GFP (iii) alleles. The 
rectangles represent the coding sequences and the thickened lines are used for homologous 
recombination to introduce GFP and NeoR in front of first exon of Pnmt. B. Southern blot 
analysis of genome DNA from screened clones shows that correct targeted allele have 8kb (5’ 
probe) and 6kb (3’probe) in addition to the wild type 14kb band. Genome DNA are lysed with 
EcoRI and XbaI. The left band in both 5’ and 3’ panel are from Pnmt-GFP knock in sample and 
right band from wild type. R, EcoRI; S, SacI; X, XbaI. This figure was by courtesy of Dr. Karl 
Pfeifer (NICHD; Bethesda, MD). 
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3.3.2 Charaterization of EGFP reporter expression in mouse adrenal glands. 
The chromaffin cells of the adrenal medulla represent the single most abundant 
location of adrenalin production and, hence, of Pnmt expression in adult animals.  Thus, 
we examined reporter gene expression in adult mouse adrenal gland tissue sections to 
determine if EGFP expression was present as expected.  In the mouse adrenal gland, 
the medulla and surrounding cortex are easily distinguishable from each other.  As 
shown in Fig. 2, EGFP expression was observed in the medulla of mice with the 
targeted Pnmt+/nEGFP allele, but was absent in wild-type (Pnmt+/+) controls.  In contrast, 
the low levels of fluorescence in the cortex are indistinguishable in wild type and in 
Pnmt::GFP animals indicating that GFP expression is specific to the medulla  and thus 
follows the patterns of the endogenous Pnmt gene.   
 
 
53 
 
 
Figure 3-2. EGFP expression in mouse adrenal glands. 
 (A & B) Low-magnification views of fluorescent imaging of adrenal gland sections from wild-
type control and Pnmt+/nEGFP mice, respectively.  Scale bar, 200 m.  (C & D)  Higher 
magnification of same image.  Scale bar, 50 m.  Ctx, cortex; Med, medulla.   
 
To evaluate the specificity of the EGFP reporter gene expression in more detail, 
we performed immunofluorescent staining for endogenous Pnmt protein expression 
adrenal gland sections from Pnmt+/nEGFP mice using a red fluorescent secondary 
antibody tag so that we could visualize both Pnmt (Fig. 3A&B) and EGFP (Fig. 3C&D) 
expression simultaneously in the same sections. Endogenous Pnmt expression is 
mainly cytoplasmic while EGFP expression was restricted to the nucleus of 
54 
 
PnmtEGFP+ cells.  Thus, overlay of the red and green fluorescent images shows co-
expression in red fluorescent cells containing green nuclei, indicating that EGFP was 
expressed in the nuclei of Pnmt-expressing adrenal medullary cells (Fig. 3, panels E 
and F).   
 
Figure 3-3. Identification of EGFP and endogenous Pnmt in adrenal chromaffin cells.   
(A & B) Pnmt immunofluorescent histochemical staining in adult mouse adrenal gland sections 
as visualized for red fluorescence (Texas Red filter).  (C & D)  EGFP expression in the same 
adrenal sections but visualized for green fluorescence (GFP filter).  (E & F)  Overlay of Pnmt 
and EGFP staining for each section.  (A, C, and E)  Lo-mag, low-magnification:  Scale bar, 200 
m.  Hi-Mag, high-magnification:  Scale bar, 30 m.     
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Confirmation that EGFP expression was principally localized to nuclei was 
obtained by co-staining the sections with the red fluorescent nuclear stain, propidium 
iodide (PI).  Within EGFP+ cells of the adrenal medulla, PI labeled the cells in a pattern 
nearly identical that observed for EGFP (Fig. 4, arrows).  Altogether these data 
demonstrate that EGFP expression is localized to nuclei of adrenal medullary cells in 
Pnmt+/nEGFP mice. 
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Figure 3-4. Nuclear localization of EGFP expression in adrenal chromaffin cells.  
(A) Propidium iodide (PI) staining of nuclei in adrenal chromaffin cells from an adult mouse 
adrenal gland section.  (B)  EGFP expression in the same section.  (C)  Overlay of PI and EGFP 
staining.  Yellow staining indicates regions of overlap. Scale bar, 50 m.    
 
EGFP expression is always confined to cells that also expressed endogenous 
Pnmt.  It is clear, however, that the EGFP expression was found in only a subset of 
Pnmt-expressing cells. We did observe that the intensity of EGFP fluorescence was 
variable in EGFP+ cells (Figs. 2-4), possibly indicating that expression may be limited in 
some cells. To partially address this issue, we compared EGFP expression in adrenal 
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sections from mice with one EGFP copy (Pnmt+/nEGFP) versus those that had two copies 
(PnmtnEGFP/nEGFP). Representative images of adrenal sections expressing EGFP are 
shown in Fig. 5 (panels A and B).  Quantitative assessment of the number of EGFP+ 
cells per section revealed that there was a significant two-fold increase in the number of 
EGFP+ cells found in the homozygous EGFP/EGFP condition compared with those 
from mice with only one copy (+/EGFP) (Fig. 5C).  Altogether, our results indicate that 
the  amounts of GFP stably synthesized in Pnmt::GFP insertion cells is variable from 
cell to cell and not sufficient to mark all adrenergic cells at any given time point. 
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Figure 3-5. Comparison of Pnmt-EGFP expression in heterozygous (Pnmt+/nEGFP) and 
homozygous (PnmtnEGFP/nEGFP) mouse adrenal glands. 
(A & B). Representative adrenal gland sections with EGFP expression from heterozygous (A) 
and homozygous (B) mice.  C. Quantitative analysis of average number of EGFP+ cells per 
section for each genotype (p < 0.05, n=5).  Scale bar, 100 m.   
 
3.3.3 Evaluation of EGFP expression during heart development in vivo and in 
vitro.  
 
In the heart, Pnmt expression is first detected during early embryonic 
development at about the time that the heart first starts to beat [30, 31].    To determine 
if EGFP expression could be identified in cardiac adrenergic cells, we examined 
embryonic heart sections from PnmtnEGFP/nEGFP mice for the presence of EGFP+ cells.  
This was more difficult than anticipated due to the relatively high background 
autofluorescence in the green spectrum.  At low magnification, it was essentially 
impossible to distinguish EGFP+ cells from non-expressing cells (Fig. 6A).  However, at 
higher magnification, however, characteristic green fluorescent nuclei were evident in 
cardiac cells (Fig. 6B, arrows) near the atrioventricular junction, a region that has been 
associated with strong Pnmt expression in the developing rat and mouse embryonic 
heart from previous studies [30, 33].  Note that the EGFP expression was not visible in 
the red spectrum, whereas nearby autofluorescent cells showed similar patterns of 
fluorescence in both the red and green spectra (Fig. 5B&C).  These data show that 
EGFP expression could be identified in presumptive adrenergic cells from 
PnmtnEGFP/nEGFP embryonic heart sections. 
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Figure 3-6. Detection of EGFP expression from PnmtnEGFP/nEGFP mouse hearts at E10.5.   
(A) Sagittal section of E10.5 mouse heart visualized in the green spectrum, with atrium (Atr) and 
ventricle (Vent) clearly distinguishable.  Scale bar, 100 m.  Although many cells appear to 
exhibit green fluorescence in this image, most of this fluorescence is due to background 
autofluorescence.  This was determined by comparing fluorescent images in the green and red 
spectra.  An example is shown in panels (B) and (C), respectively.  Note that the images shown 
in panels B & C represent an expanded view of the region of the E10.5 near the A-V junction 
(boxed region from panel A) representing green and red fluorescent images, respectively.  The 
EGFP+ cells (arrows) were positively identified with the green fluorescence filter showing EGFP 
expression to be exclusively evident when visualizing green but not red fluorescence.  In 
contrast, autofluorescence was observed similarly in green and red spectra.  Scale bar, 20 m.  
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As an alternative approach to these in vivo assessments, we examined 
endogenous Pnmt in mESCs and EGFP reporter expression in Pnmt+/nEGFP mESCs 
before and after inducing their differentiation into beating cardiomyocytes [99, 100]. As 
shown in Fig. 7A, Pnmt mRNA was not detected in undifferentiated pluripotent mESCs 
(lane 1), but appeared subsequent to the onset of contractile activity at 7+3d (lane 2), 
and continued to be associated with beating cardiac-differentiated mESCs at 7+5d (lane 
3). Thus endogenous Pnmt mRNA is restricteded to mESCs that had been induced to 
differentiate into beating cardiomyocytes, and is not detectable in undifferentiated 
mESCs.   
 Evaluation of EGFP expression in these mESCs uncovered small clusters of 
EGFP+ cells as early as 7+3d (Fig. 7B).  We used the same criteria as above (green 
fluorescence in cell nuclei showing no autofluorescence in the red spectrum), and found 
no clear EGFP staining in undifferentiated mESCs (not shown).  The staining that was 
observed after induction of cardiac differentiation was observed in a relatively small 
number of cells, and was often difficult to find.  It did not appear that there was 
appreciable EGFP expression in the beating cardiomyocytes themselves, but small 
clusters or isolated patches of EGFP positive cells like those shown in Fig. 7B were 
found adjacent to or near areas of beating activity.  These results show that EGFP 
expression was induced in association with heart development in Pnmt+/nEGFP embryonic 
cells both in vitro and in vivo.           
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Figure 3-7. Induction of cardiac differentiation and activation of Pnmt and nEGFP 
expression in mouse ES cells.   
(A)  Endogenous mouse Pnmt gene expression as detected by RT-PCR before and after 
induction of cardiac differentiation in mouse ES cells.  This procedure takes (7 + n) days.  (B)  
Image of nEGFP+ cells in 7+5d cultures of cardiac-differentiated mouse ES cells.  Scale bar, 50 
m. 
 
3.4 Discussion 
 
In this study, we have described the initial characterization of a new mouse 
model where a nuclear-localized EGFP reporter gene was inserted into the endogenous 
mouse Pnmt gene locus to create heterozygous Pnmt+/nEGFP and homozygous 
PnmtnEGFP/nEGFP mice.  Our results showed that nEGFP reporter gene expression was 
specifically found in adrenergic chromaffin cells of the adrenal medulla based on co-
expression with endogenous Pnmt protein in these cells.  Nuclear localization of the 
signal was confirmed by co-labeling the cells with the nuclear dye, propidium iodide.  
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We also demonstrated expression of nEGFP near the atrioventricular junction region of 
the developing mouse heart in vivo, and in association with endogenous Pnmt 
expression in mESCs after they were induced to differentiate into beating 
cardiomyocytes in vitro.  These initial analyses indicate that the nEGFP reporter gene is 
correctly targeted and expressed in adrenergic cells in the adrenal glands as well as 
those associated with embryonic heart development.  Although further characterization 
is needed to evaluate reporter gene expression in more detail at different developmental 
timepoints and in other tissues known to express endogenous Pnmt such as retinal 
neurons, brainstem neurons, lymphocytes, lungs, liver, spleen, kidney, and testes [7-12], 
these initial results suggest that nEGFP expression successfully identifies Pnmt-
expressing cells in mice.   
 The Pnmt+/nEGFP mouse model provides two distinct advantages compared with 
similar knock-in models that inserted the Cre-recombinase gene into the mouse Pnmt 
locus [33, 101].  First, the nEGFP knock-in marks cells actively expressing Pnmt while 
the Cre knock-in marks cells that had a history of expressing Pnmt at some point in their 
development in addition to cells actively expressing Pnmt.  Second, EGFP can 
potentially be used to identify and isolate viable adrenergic cells directly using 
fluorescence imaging and collection strategies such as fluorescence-activated cell 
sorting (FACS).  When comparing the staining results from these models, it appears 
that the Pnmt-driven nEGFP expression is restricted to a subset of cells that showed 
positive expression of Pnmt-driven Cre-recombinase from previous studies [33].  To 
identify cells that had expressed Cre-recombinase, the mice were crossed with 
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ROSA26 reporter mice containing the β-galactosidase reporter gene.  Within the 
adrenal glands, β-galactosidase staining was restricted to the adrenal medulla.  In 
contrast, β-galactosidase staining in the heart was initially found in the muscle walls of 
the cardiac chambers of the developing embryonic heart, similar to the nEGFP staining 
patterns observed in the present study.   
 It should be noted that the targeting vectors and strategies were similar for both 
models (nEGFP and Cre), so we expected some similarity in expression patterns that 
also matched those observed for endogenous Pnmt staining.  The more limited staining 
observed in the nEGFP knock-in model undoubtedly reflects the fact that only active 
Pnmt-expressing cells show nEGFP expression compared with the active plus historical 
expression demarcated by the β-galactosidase reporter generated by Cre-activation of 
the ROSA26 locus [33].  When compared to endogenous Pnmt expression using anti-
Pnmt immunofluorescent staining techniques, we also found only a subset of active 
Pnmt-expressing cells that also displayed nEGFP reporter expression.  Our analysis 
suggested that this is a sensitivity issue.  At any given time, many adrenergic cells have 
not expressed enough EGFP to effectively mark the nucleus above the fluorescent 
background.  In this regard, the variability in GFP fluorescence between cells is quite 
interesting as it suggests that the activity of the medullary cells is not uniform.  We hope 
to use our system to characterize this cell to cell variability in future studies.  
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3.5 Limitations and Future Directions 
 
Although EGFP is widely employed as reporter gene, recent studies show 
several disadvantages for its application in mouse ES cells and transgenic animals [35, 
36].  The spectrum of EGFP fluorescence overlaps with background autofluorescence, 
which poses challenges for distinguishing EGFP+ cells from non-expressing cells.  This 
is especially true when reporter gene expression is relatively weak or at low abundance, 
as was the case in the embryonic heart.  Improved fluorescence imaging techniques 
and equipment should help resolve the autofluorescence challenges, which were also 
partially overcome in the present study by comparing fluorescence images in the red 
and green spectra.  Specific EGFP+ fluorescence was only observed in the green 
spectrum, whereas autofluorescence has a much broader bandwidth and is evident in 
both green and red spectra on our microscope. 
In addition to the challenges posed by autofluorescence, we also observed 
considerable variation in EGFP+ cell staining within tissues that express Pnmt.  This 
was most clearly seen in the adrenal medullae where many Pnmt+ cells did not display 
detectable EGFP expression.  Other studies have also noted variable expression for the 
EGFP reporter in mammalian cells.  For example, Swenson did a systemic analysis of 
GFP transgenic mouse using three different types of GFP mice strains with “ubiquitous” 
promoters and various methodologies for data acquisition, such as direct fluorescence 
detection, immunofluorescence and immunohistochemistry with diaminobenzidine, 
(DAB) deposition. GFP expression characteristics were also determined in various 
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organs [17]. Notably, GFP expression in different organs varied widely between the 
three genotypes tested, and the differences from same organs were also significant.  No 
matter which promoter was used to drive GFP expression, not all the cells from 
examined tissues were GFP+ in any of the three transgenic lines.  There may be 
inherent limitations in the GFP reporter gene itself, perhaps due to toxicity, turnover, 
nuclear reprogramming, and/or other effects of GFP and its derivatives that have yet to 
be fully defined.  Thus, the main limitations of the model appear to primarily concern the 
variability of the EGFP reporter and difficulties in distinguishing its expression from 
background autofluorescence when in low abundance, such as the case observed 
during embryonic heart development. 
 
3.6 Conclusions 
 
Despite the limitations of the EGFP reporter indicated above, we have 
nevertheless shown that this reporter gene was correctly targeted to the mouse Pnmt 
gene locus.  Further, we successfully created a new mouse genetic knock-in 
Pnmt::nEGFP model that expresses nEGFP exclusively in Pnmt+ cells.  In no cases did 
we find nEGFP expression that was inconsistent with endogenous Pnmt expression.  
Expression was verified in adult adrenal chromaffin cells as well as embryonic cardiac 
cells.  This model should be useful for identification and characterization of adrenergic 
cells in a variety of other tissues/cells also known to express Pnmt, such as retina, 
brainstem, lung, testes, lymphocytes, and others [25, 26, 29, 97, 102-106]. 
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CHAPTER 4 : GENERATION OF NOVEL FLUORESCENT 
REPORTER CELLS FOR IDENTIFICATION OF CARDIOMYOCYTES 
DERIVED FROM ADRENERGIC PROGENITOR CELLS  
 
4.1 Introduction 
 
In the chapter III, we used a genetic model to determine whether the specific 
population of cardiac adrenergic cells occurred during embryonic heart development, in 
which PNMT regulatory sequences to control the transcription of EGFP, thus enabling 
us to characterize the live cells with adrenergic phenotypes. Although EGFP is a strong 
reporter gene under most cases, and we did observe the green fluorescent cells in the 
embryonic heart, however, as for multiple reasons, the signal was not strong enough to 
identify these adrenergic cells in addition to other complexities which made it difficult for 
isolation of these cells, no matter in vitro PNMT-nEGFP ES cells or the embryonic 
hearts of PNMT-nEGFP mice are used. Therefore, genetic models with higher 
specificities for reporter genes should be developed to improve the shortcomings of the 
current model.  
As our purpose is to study the cell lineage and final destinations of adrenergic 
derived progenitor cells, so mESCs are very important tools to fulfill the purposes for the 
following reasons. First of all,  pluripotent mESCs have the capability of self-renewal 
and differentiation to multiple cell types and organs, which include cardiomyocytes [100, 
107-109], thus they are good tools to study the gene regulation of cell lineage 
commitment during embryogenesis,  and can give us detailed information of specific 
67 
 
tissue or organ morphogenesis such as cardiac development. Mouse mESC cells are 
good models to explore the mechanisms of cardiogenesis and also vasculature 
development [110, 111] . 
Secondly, current molecular biology technologies allowed us to do plenty of 
genetic manipulation of ES cells (knock-in, knock-out and et al) and these engineered 
ES cells still keep the features of self-renewal and differentiation, even incorporation 
into embryogenesis when transplanted back into early embryos [112-114]. Thus, we can 
have variety of genetic engineered animal models in which the gene of interest was 
altered, therefore, we can identify their phenotypes to determine the function of specific 
gene at specific tissues, and also at specific time frame. Thus establishing a proper 
engineered mESC model can help us accomplish our own research objective if the 
mESC line can provide detailed information about the intrinsic adrenergic derived 
progenitor cells.  
Cre recombinase which was identified in phage P1, can excise the 34bp lox-P 
site through recombination and results in deletion of the sequences between two lox-P 
sites [115, 116]. This capability to delete sequences from double strand DNA makes 
Cre useful in various biological applications, especially in the gene targeting [117].  It 
can lead to activation or inactivation of specific genes, both endogenous and transgenic, 
and this process can be through temporal, spatial or cell type specific induction [118],  
allowing us to explore the functions of these genes at specific milieu. In addition, under 
proper situations, some specific cell populations can be deleted [119, 120].    
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Recently, a double fluorescent indicator vector was engineered by Hescheler and 
colleagues [37]. This vector (as outlined below) has several characteristics: 
 
Figure 4-1. Map of the dual fluorescence plasmid βRBPIG. 
MluI, AscI and BspHI are the recognized sites of individual restriction endonuclease; 
CAGGS, chicken β-actin-promoter with CMV enhancer; HcRed, coding sequence for 
the RFP HcRed1; BsdR, resistance against the antibiotic blasticidin; WSS, Westphal 
stop sequence; PAC, puromycin acetyltransferase; IRES, internalribosome entry site; 
GFP, green fluorescent protein; Amp, resistance against ampicillin with bacterial 
promoter; picture is by the courtesy of Kurt Pfannkuche et al [37].  
 
 
1. The Multiple cloning sequence (MCS) of the plasmid is divided into two parts: red 
fluorescent protein (RFP) encoded by HcRed1 gene and enhanced green 
fluorescent protein (EGFP).  
2. The RFP coding sequences is followed by blasticidin resistance and a stop 
sequence called Westphal stop sequence (WSS), HcRed-Bsd-Wss is flanked by two 
loxP sites on each ends. 
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3. Behind the second loxP site, the construct contains Puromycin resistance gene 
which encodes Puromycin acetyltransferase (PAC) and PAC is linked with elements 
for internal ribosome entry site (IRES) plus EGFP. The PAC-IRES-EGFP bicistronic 
expression cassettes will only be expressed when Cre is available and excise the 
flanked HcRed-Bsd-Wss sequences. Thus, this vector provides the opportunity of 
discrimination of unrecombined and recombined cell populations dependent on the 
Cre activity. 
4. This vector’s promoter is from chicken β-actin and its enhancer from 
cytomegalievirus (CMV) immediate early gene, the promoter is extremely attractive 
as it is fully functional in mESCs.In addition, as RFP and EGFP have different 
antibiotic resistance (blasticidin vs puromycin), it allows us to get high yield of 
purified either unrecombined or recombined cells by drug selection respectively. 
With this powerful Cre indicator vector, researchers can employ it for many ways 
other than originally designated as a measure for monitoring cell fusion events. For 
example, if one gene’s regulatory elements (including promoter and enhancer) are 
linked with Cre coding sequence, cells under the regulation of this gene are possibly 
mapped by introduction of this dual fluorescence vector in cultured cells based on the 
switches of fluorescence, as only cells with emission of green fluorescence are those 
regulated by target gene, the activity of which can be illustrated by excision of loxP 
sequences from Cre. In addition, this specific type of cells can be enriched by 
administration of puromycin.  
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Based on our previous results, Pnmt mRNA was only expressed in mESCs after 
differentiation into cardiomyocytes. Thus in this section we developed a strategy \that 
the pluripotent mESCs knocked in with Pnmt-Cre were utilized as the starting materials, 
the Cre indicator vector was stably transfected into this mESC line. Therefore, after in 
vitro differentiation of these engineered mESCs into beating cardiomyocytes, 
fluorescence changes will be tracked to determine the activity of this conditionally 
expressed Cre. This is a simpler in vitro model to fulfill the purpose of characterizing 
adrenergic progenitor cells, and if the hypothesis performs well, we have the opportunity 
for enrichment of the cells with adrenergic phenotypes which we can use for further 
identification of their physiological properties.  
 
4.2 Material and Methods 
 
4.2.1 Materials 
All the medium (DMEM, high glucose, containing L-glutamine and sodium 
bicarbonate) and supplements such as Non-essential amino acids (NEAA), L-alanyl 
glutamine (GlutMAXTM), β-mecaptoethanol, Pen-Strep were from Invitrogen, 0.05% and 
0.25% trypsin both with EDTA were also from Invitrogen, Fetal bovine serum defined 
grade from Hyclone (SH30070.03 ), ESGRO®(LIF) Supplement (107 Units) and gelatin 
were from Millipore, Blastidicine S Hydrochloride (15205, ≥99.0%), Puromycin 
dihydrocholoride (P7255, ≥98%), Mitomycin C (M5053) were from Sigma. Glass-bottom 
dishes, P35G-1.5-14-C was from Mat Tek corporation. Regular 96, 48 and 24 well 
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plates and tissue culture dishes with 20mm grid were from Falcon, regular 10cm, 6cm 
petri dishes and T25, T75 flasks were from Corning Corporation.  
4.2.2 Primary cultures and maintenance of mouse embryonic fibroblasts (mEF) 
All the procedures were in accordance with ATCC cell culture protocols with 
minor adjust. For primary cultures of mEF, mouse fetus at post-cotium 11.5 to 13.5 from 
129sv strain pregnant mice were antiseptically removed from opened uterus and 
transferred to sterile PBS containing petridishes. After removal of placenta and all 
visible membranes, viscera and other clear organs such as head and tail of fetus were 
also taken out and then transferred to another petri dish. The remaining tissues were 
minced with dissection scissors as small as possible, and then put to 50ml cornical tube. 
Trypsin (0.25%)/EDTA was added to the tube and tissues were dissociated by pipetting, 
incubated at 37C for 5 to 10mins dependent on the numbers of fetus. The digested 
product were neutralized with DMEM full medium (10% FBS) and settled for 5mins to 
precipitate large and undigested pieces. The supernatant were then transfered to 2-3 
10cm petri dishes. Cells were incubated at 37°C for 24h and processed with medium 
change thereafter. After incubation for another 24h, cells were split with 0.05% trypsin at 
the ratio of 1 to 3 and cells at this passage were marked at P1. mEF at P2 and P3 were 
frozen for future usage. Usually, the mEF kept good proliferation rate until their 7 to 9 
passages and after stop proliferation they were not used as feeder layers. 
4.2.3 Mitomycin C treatment of mEF as feeder layers fro mESC 
After the mEF were 90% confluent in either petri dishes or tissue flasks, they 
should be treated with mitomycin C to stop their proliferation thus become ideal feeder 
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layers for mESC. Medium was changed and Mitomycin solution (0.5mg/ml) was diluted 
with DMEM to final concentration of 10μg/ml. Cells treated with drugs were incubated at 
37°C for 3 to 3.5hr, then rinsed with PBS twice and trypsinzed and collected. Usually we 
use condensation ratio at 1:1.2 to 1:1.5 to reseed the re-suspended mEF to either 6cm 
petri dish or T25 flasks. Condensation ratio was designed as the ratio of the whole 
covered surface areas before Mitomycin C treatment with the whole growth areas after 
treatment. The reason for thicker seeding densities after drug treatment was because 
some of mEFs would become less healthy after this process thus higher density was 
required. Since being seeded, mEF could be ideal feeder layers for two weeks.   
4.2.4 Mouse embryonic stem cells culture 
Mouse ES cell line used in current part was pre-engineered R1 mESCs with 
Pnmt-Cre [33]. Standard culture protocol for ES cells includes medium change every 
day and split at ratio of 1:5 to 1:7 regularly every other day. The medium should contain 
mouse leukemia inhibitory factor (LIF or ESGRO®) at 1000 units/ml. Most of the time, 
mESC should be cultured on mEF feeder layers as these are the most close in vivo 
growth milieu for them. For some cases, such as differentiation, ES cells can grow on 
gelatin (0.1%) coated culture dishes for couple of passages but not for long term 
maintenance. When grown on mEFs, 0.25% trypsin/EDTA was used to split mESCs 
when cells were 70% confluent, however, 0.05% trypsin/EDTA was used for ES 
cultured on gelatin.  
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4.2.5 Generation of stable double fluorescent indicator ES cell line 
4.2.5.1 Linearization of RBPIG plasmid 
The RBPIG Cre/loxP vector was digested with MluI overnight at 37°C, confirmed 
for complete digestion by running small amount digest product through agarose 
electrophoresis. There should be only one 12kb band on the gel. The whole 100μl 
product were then purified and precipitated with 70% ethanol, re-suspended in 30μl 
sterile electroporation buffer. The total DNA was for one electroporation was around 30-
40μg. 
4.2.5.2 Electroporation of mESC with linearized RBPIG plasmid 
Pnmt-Cre mESCs with lower passages were split one day before electroporation. 
These cells were trypsinized to single cell suspension. After neutralization, cells were 
washed twice by PBS through centrifugation, after cell counting with hemocytometer, 
around 3x107 cells were re-suspended in 600μl electroporation buffer, linearized DNA 
was added and balanced with more buffer to final 800μl. The cell suspension were 
transferred to 0.4cm cuvette (Biorad), put on the ice for 5min before electroporation. 
Here we used more hash parameters for the electroporation as the preliminary 
studies showed that these parameters achieved to higher cell clones compared with 
other milder ones. With Bio-Rad Gene Pulser XcellTM electroporation system, 260V and 
500μF capacitance were chosen for elctroporation with the module of exponential decay. 
The time constant often fell into 10-12msec. Cells were returned on ice for another 5min 
before being transferred and seeded into 30 6cm feeder layer coated petri dishes. 
Relevant control groups were also set up which included: 1) Mock electroporation, cells 
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were electroporated without DNA; 2) Normal cells without electroporation; 3) &4) RBPIG 
and Mock electroporation but without the addition of drugs (detailed as follows). 
4.2.5.3 Screening mESC clones with stable transfection of RBPIG 
One day after electroporation, medium was changed with addition of 3μg/ml 
blasticidin, then medium was changed every other day with fresh blasticidin. The cells 
looked all dead around day 7 after drug treatment, thereafter, small colonies gradually 
came out. On day 14, colonies were picked out under the microscrope by pipets and 
transferred to 96 well plates, dissociated with 0.25% trypsin/EDTA, then transferred to 
48 well plates pre-covered with mEF. All the selection procedure contained drugs. 
When colonies became half confluent in 48wells, they were processed as same above 
and dissociated cells were switched to 24well plates. During the selection, each colony 
was marked numerically and caution should be paid to avoid the cross-contamination 
between colonies.  
When cells in the 24wells were half confluent, cells were dissociated and divided 
into two parts. Half of the cells were frozen and the second half was seeded onto 3.5cm 
glass-bottom dishes covered with gelatin. As for the slim thickness of the glasses in the 
center of these culture dishes, cells growing on them were easily detected under the 
microscope. 
We use Spin-disk confocal laser microscope (Perkin Elmer) for the screening of 
live fluorescence for each individual cell clone. The transfected undifferentiated ES cells 
should emit red fluorescence, and based on the spectrum characteristics of HcRed1 
(Maximum Excitation at around 590nm and emission at 645nm), we chose relevant 
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fluorescence filter to achieve highest fluorescence yield. During the screening, the 
exposure time and compensation were set up same for each sample for fair comparison 
of the fluorescent intensities. Each sample should get a number representing the 
maximum fluorescent intensities. Pictures were also taken for some clear positive 
transfectants. In the first round of screening, we mainly relied on the absolute reading 
and pictures to judge their fluorescent activities. Around 30 different colonies were 
selected as positive during the first round screening. These colonies went through the 
same protocol for comparison during the second round live imaging screening and the 
numbers of highest transfected colonies were narrowed to single digit.  
In the same time, the selected colonies were maintained for around 10 passages 
for observation of their ES characteristics: speed of proliferation, self renewal 
capabilities and morphology, any colonies with abnormal characteristics, especially with 
big morphology change (indication of self differentiation or other biological changes) 
should be excluded. The final two to four clones were chosen and by confocal scanning 
their 3D structures were taken. In addition, their detailed passage information was kept 
in records.  
4.2.5.4 Purification of RBPIG colonies by single cell clonal analysis 
As for some reason the colonies we got above had lower percentage of RFP 
positive expression (would be explained in detail in the discussion part), we utilized 
single cell culture to get much purer population of fluorescent positive cells. The two 
colonies we chose were the start of these purification processes. For each cell line, cells 
were seeded 1 cell per well theoretically based on the counting from hemacytometer in 
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48 well gelatin covered plates. The medium also included blasticidin at desired 
concentration. After two weeks or so, some wells could be found with formation of small 
colonies, through regular medium change and drug refreshing, some colonies continued 
to grow, we then used epifluorescence microscope to detect the red fluorescence of 
these cells. Several wells emit much higher fluorescence than others so cells from these 
wells were candidates for further purification. Cells from these wells were marked and 
reseeded at very low densities (around couple of hundred cells per well in 48 well 
plates). Each subclone had 5 to 7 sub-subclones, for example, cells from clone No.3 of 
original clone No.34 were reseeded and named Clone 34-3-1, 34-3-2, 34-3-3, etc. 
These clones were checked for their fluorescence both in 48 well plates and also on the 
glass-bottom petri dishes to determine the fluorescent intensities. These clones were 
then seeded on 6cm petri dishes covered with mEF and the spouted clones had much 
more even distributed fluorescence on average and thus the selection ended at this 
point. Totally there were 2-3 final candidates which were used for the differentiation 
studies.  
4.2.6 Cardiac differentiation of RBPIG mESC into cardiomyocytes 
There are several ways to differentiate mESC into cardiomyctes in vitro [121], 
such as Haninging drop, the method in the chapter III employed, suspension culture in 
bacterial-grade dishes and etc. However, Hanging drop method is still the most often 
used tool which cells were allowed to aggregate to form embryonic bodies (EBs) in the 
bottom of a hanging drop [107]. In this chapter, we mainly used this method to induce 
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cardiac differentiation in vitro, although at less frequency rotary suspension culture was 
used as alternative. 
For Hanging drop culture, it is introduced briefly as in previous chapter but will 
amply described here. Early passage mESCs were split into individual cells and 
counted, 500 cells per 20μl differentiation medium (without LIF) were put on the lid of 
150mm petri dish as a drop, the bottom of the dish was covered with PBS in order to 
avoid dryness. After finshing dropping, the lid was swiftly reversed and placed on the 
dish which was then incubated at 37 °C. After 2days, the lid was flipped, and the white 
EBs were transferred to two 10cm bacterial grade dishes within 10ml differentiation 
medium. At this moment, there’re two ways to continue the culture, one is by stationary 
culture, dishes were just put back into incubator, the second way relied on a horizontal 
rotating device located in the incubator to make these dishes rotate at 35rpm during 
growth. For both ways, EBs were in suspension for 2 to 3 more days and then 
transferred to gelatin coated cell culture dishes. Medium was changed every other day 
thereafter, EBs were attached first and then gradually stretched out, mesoderm derived 
cardiomytes were usually in the middle part of the whole differentiated structures, and 
these were the main observation fields where beating foci could be found. The beating 
activity started around 7 to 8 days since start of differentiation, and occasionally these 
could be delayed by several days. The rate of contraction increased gradually since the 
start of beating and contraction could last for at least 3weeks, then beatings stopped 
and cells became almost fully differentiated and cardiomyocytes occupied a big portion 
of these cells.  
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For some cases, we use rotary suspension cultures to yield differentiated cells 
from the beginning. The method was mainly based on the protocol from McDevitt’s 
laboratory but with minor modifications [122, 123]. Basically, undifferentiated ES cells 
were plated at 4x105/ml into bacterial grade dishes within 10ml differentiation medium. 
As mentioned above, dishes were put on the surface of an orbital rotary shaker at 
around 35 revolutions per minute. The speed was very critical for the quality of EB 
formation as cells were inclined to aggregate into big clumps instead of EBs at lower 
speed, and with speed of 45rpm and above, the numbers of the EBs were sharply 
reduced plus the size was also much smaller. We tested several suggested speeds and 
chose the above one for most of the experiments. After two days in suspension, the 
EBs containing medium was carefully transferred to a sterile 15ml conical tube and 
settled down for 5mins. The supernatant was then discarded and EBs were gently 
mixed with new medium and seeded into two new dishes. Medium was changed every 
other day and the culture was kept for 5 to 7 days in suspension, then EBs were plated 
into 6cm or 10cm gelatin coated dishes at about 30 and 70 per dish respectively. After 
being plated, it was treated as above with hanging drop method and EBs’ morphology 
changed from round dark core to more spread out multilayer cells 3-4 days later.  
4.2.7 Puromycin treatment of cardiac differentiated mESC clones transfected 
with RBPIG  
 
Puromycin was dissolved at 10μg/ml at stock and aliquot was kept at -20°C. In 
order to determine the concentration which kills the non transfectant at minimal amount, 
a dosage curve was made for undifferentiated mESCs. Confluent mESCs in 6cm petri 
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dishes were treated with puromycin at different concentrations from 0.5, 1, 2, 3 to 
5μg/ml in full medium. The morphology change was carefully monitored after drug 
induction every day. The concentration which killed cells almost completely after 48h 
was chosen as the base concentration in differentiated cardiomyocytes. The 
concentration was set between 1-2μg/ml.  
Cultured differentiated ES cells by both methods (Hanging drop or rotary 
suspension) were treated with puromycin at different stages. Initially, we treated 14d 
differentiated cells in 6cm petri dishes with 2μg/ml and change medium 2days later if 
cells were not completely dead. Later on, drugs were administrated starting from day 8, 
10, 12 and also refreshed every other day. Comparison of morphology was made 
between Pnmt-Cre cells and mESCs transfected with RBPIG.  
 
4.3 Results 
 
Initially we picked up 204 colonies into 48 well plates, some of which still survived 
the antibiotic treatment, around 100 colonies were cultured in 24 well plates, again the 
resistant clones were further cultured in 3.5cm petri dishes for fluorescence screening 
by microscope. We screened about 90-100 colonies by checking fluorescence under 
both green and red fluorescence filters. The maximal emission spectrum of HcRed1 is 
around 645nm, so a specific fluorescence filter, rather than regular red fluorescence, 
was chosen for fluorescence detection. Among the screened samples, 24 colonies 
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which were red fluorescent based on same evaluation rule (detailed in materials and 
methods) were screened for the second time, with both fluorescence intensity and 
morphology taken into consideration. For example, some clones show positive red 
fluorescence, however, there were some cells undergoing self-differentiation with 
“dendrite” like cells stretching out from main mESC cell clusters. Clones like the above 
described won’t be designated as a good one and thus excluded. Finally, we chose 
No.34 and No.46 as the final candidates for the following experiments, both showed 
well above-background red fluorescence and good morphology. Representative pictures 
are shown in Fig.2.  
 
Figure 4-2. Red fluorescence of mESC clones from Pnmt-Cre mESC transfected with 
RBPIG. 
No.34, one of the positive clones from Pnmt-Cre mESCs transfected with RBPIG, 
showed red fluorescence after blasticidin selection. (A), red fluorescence image; B, 
phase-contrast and C, overlay of the fluorescence and phase-contrast images. pictures 
were taken under 10X. Scale bar: 26μm.  
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In order to see whether green and red fluorescence could be found after 
transfection, we used HEK293 cells as a control and transiently tranfected them with 
pEGFP-N1 and RBPIG respectively to determine whether fluorescence could be 
detected from these transfected cells. Fig. 3 showed that both GFP and RFP could be 
detected after transient transfection, thus providing a good control for the identification 
of green and red fluorescence of mESCs.  
 
Figure 4-3. Fluorescence of HEK293 cells transiently transfected with pEGFP-N1 and 
RBPIG respectively.  
HEK293 cells were tranfected with pEGFP-N (A) and RBPIG (B) by calcium phosphate 
precipitation in 3.5cm bottom glass petridishes. 48hrs after transfection, fluorescence 
was determined by confocal laser scanning microscopy. Pictures were taken at 25X and 
showed as overlay of phase-contrast and fluorescence.  
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Then No. 34 and No.46 RBPIG clones were differentiated into caridomyocytes by 
hanging drop. After 2-3days in stationary suspension, EBs were attached to gelatin 
coated petri dishes. They started to beat on average 7-8 days since differentiation. The 
overall beating activity was consistent, with the majority of the seeded EBs could 
occupy at least one beating loci, albeit the number and physical size of the beating loci 
highly varialble. We determined their fluorescence 15 days after differentiation and 
representative pictures were shown as follows.  
 
Figure 4-4. Fluorescence switch of cardiac differentiated Pnmt-Cre/RBPIG mESCs. 
Images of RBPIG mESCs of clone No.46 on glass bottom culture dishes at 15 days 
after cardiac differentiation. (A) green fluorescence; (B), red fluorescence; C, overlay of 
A and B. All the pictures were used phase contrast images as background. Scal bar: 
7μm. 
 
Differentiated mESCs from both hanging drop and rotary suspension culture 
were also treated with puromycin. As for the chosen dosage (0.5-5μg/ml), there were 
not significant discrepancies of morphology changes between the transfectant and 
control. Further discussions were in the next part of the same chapter and alternative 
strategies for enrichment of these green fluorescent cells were also covered. 
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4.4 Discussion 
 
In this section, we used a dual fluorescence plasmid as the indicator, to monitor 
the Cre activity by observation of fluorescence switches, this is an straightforward way 
to determine how does Pnmt exert its function during cardiac differentiation, since the 
Cre activity is fully controlled by Pnmt.  
In the figures we showed above, we successfully established the mESC line 
transfected with this construct, red fluorescent cells were identified and continuously 
enriched with antibiotic (blasticidin) inclusion and around 20 or so cell lines were 
confirmed with positive. After comparison of fluorescence intensities, two out of these 
20 were finally chosen as further experimental purposes. They both could differentiate 
well into beating cardiomyocytes, and representative picture for clone No.46 in figure 4 
showed the occurrence of fluorescence switch after cardiac differentiation into partial 
mature cardiomyocytes (15 days since differentiation). Specifically, these fluorescence 
emitting cells were located in the beating areas. These results demonstrate that this in 
vitro mESC differentiation successfully imitates the developmental process of 
cardiomyocyte differentiation in vivo. In addition, Pnmt is involved in this molecular 
process as its regulation is represented by Cre activation and excision of the RFP part 
of RBPIG, resulting in a portion, although not many of the differentiated cardiomytes 
with green fluorescence. This is a critical discovery which confirmed our previous data 
that showed Pnmt expression and participation in the early stages of mouse and rat 
heart development [30, 31, 33].  
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Fluorescent protein used in biological science is a revolution as the technology 
allows us to investigate a variety of biological functions such as the protein localization, 
dynamic movement and mutual interaction. Among these families GFP was discovered 
first and also most widely applied in practice. However, red fluorescence protein was 
used much less for some reasons. One reason was fewer numbers of RFP proteins and 
their mutant variants available. The other reason originated from the structures of these 
proteins. RFP was usually tetramers and produced toxicity as there were aggregates in 
the cells. It was difficult to get RFP expression in murine embryos if the natural forms 
were not modified.  
The most commonly used RFP was DsRed and HcRed. DsRed has gone 
through several generations of strutcture modifications, such as monomeric RFP 
(mRFP), which has been successfully applied for generation of mESCs and transgenic 
mouse [124, 125].  
Another far-red fluorescent protein, HcRed, was discovered through site-directed 
and random mutagenesis on a non-fluorescent chromoprotein (hcCP) isolated from the 
Indo-Pacific Anthozoa species Heteractis crispa. HcRed1 was generated through series 
of molecular modifications and commercially available by Clonetech as a vector, and 
this vector provides the cDNA of HcRed1 and was processed through multi-step 
subclones to form RBPIG. HcRed1 forms dimers instead of tetramers, thus enhancing 
the performance as a fluorophore. The wavelength is sharply shifted to maximum 
excitation wavelength at around 645nm [126]. This long wave length fluorophore has 
several advantages: longer wavelength emissions have lower background 
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autofluorescence in tissues, thus increasing the tissue penetration and leading to fewer 
overlays with other fluorophores. When HcRed was just discovered, researchers 
successfully used it for generation of transgenic embryos and new born mice, however, 
the long-term survival condition was unknown [127].  
Although HcRed1 was already improved compared with those original versions 
which were tetramers, the dimeric form still has some serious problems. Based on the 
comparison with other available RFP, HcRed1 still forms obligate aggregates, showing 
that it is still a not very mature protein tag [126]. In addition to its low brightness 
compared with others [128], the cytoplasmic background was also higher than others. 
Those phenotypes possibly explained the practical issues when we transfected mESC 
with RBPIG plasmid. The transfection efficiency was fairly low during initial screening, 
only 15 to 20% of the total cells emit red fluorescence. We don’t know exactly the 
reason for the lower transfection ratio at the moment. One of the possible reasons could 
be from the characteristics of HcRed1 fluorophore itself. On the other hand, the CAGGS 
promoter was confirmed functional in murine mESCs. This promoter plus CMV enhance 
should drive the following RFP codons at high expression levels, considering we used a 
very hush electroporation parameter (260V, 500μF). Although we used single clone 
analysis protocol to grow one ES cell and tried to get higher population of red 
fluorescent cells, this adjustment did increase the proportion of red fluorescent cells to 
some extent (compared with unpurified ES clones), it has to be recognized that positive 
cells still accounted only a portion of the whole populations instead of 80-90%. Up to 
now, there was no monmeric version of this fluorophore available, and another modified 
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dimeric version, tanderm dimers which has two head-to-tail linked HcRed1 molecules, 
the performance of which was also improved compared with HcRed1 [129]. Thus, the 
heterogeneity for the RBPIG transfection could be improved by discovery of new 
version of RFP.  
After differentiation in vitro, partial cells will become cardiomyocytes [99, 107, 
130]. Cardiomyocytes originate from mesoderm, thus the beating loci usually fell into 
just outside of EB core. We did see beating loci from different batches of cells after 
differentiation, and the beating period could last for 3 to 5 weeks since starting. Hanging 
drop is the major way to let the pluripotent ES cells fully differentiate into beating 
cardiomyocytes, although other reports suggest other methods, such as orbital rotary 
suspension culture which make cells aggregate during continuous shaking by outer 
forces could also yield beating cardiomyocytes [122], however, in our own conditions, 
the beating loci from the later method were very few, and their morphology were not as 
fully stretched out compared with those from Hanging drop. Therefore, suspension 
culture didn’t get the same level of differentiation quality in vitro as Hanging Drop did. 
The other factors, such as difference of each serum lot we used may also play 
important role. It deserves further effort to optimize the protocol of rotary suspension 
culture as higher yield of EBs could be achieved, when large scale experiments are 
demanding. We mainly used suspension culture for drug enrichment experiments as 
there were almost even numbers of cells in a single culture dish if initial inputs were set 
at same, therefore, antibiotic selection by puromycin will be more consistent. 
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However, after puromycin treatment, there were almost no obvious difference for 
survival cells between RBPIG transfectant and control (Pnmt-Cre) cells. We tested 
various concentrations, which ranged from 0.5 to 3μg/ml, and the starting time of drug 
administration was also variable, from around one day to 2weeks after EBs seeded on 
gelatinized dishes (Earlies at day 6 from starting differentiation). The main purpose of 
employment of broad time course is to seek a particular window with highest Cre 
expression. Our results from Pnmt-nEGFP differentiated mESCs demonstrated that 
Pnmt transcripts could reach to highest level between 10-12 days after cardiac 
differentiation. The expressions of Pnmt in Pnmt-Cre ES cells should be similar with 
those from Pnmt-nEGFP. Among all the dosage tested, beating loci could be kept after 
1-2 days since puromycin administration, but they were gradually lost, the morphology 
of which wouldn’t be distinguished from the nearby cells which were dead much earlier.  
Nevertheless, in each single experiment, there were always some left over cells which 
looked like alive based on visual observation, especially from 1 to 2μg/ml dosage group, 
although similar cells, not always, but sometime also were found from the control group. 
So it deserves a strategy to further identify these differentiated cells, if antibiotic 
selection can be combined with other methods, such as FACS, which could quantify 
and isolated the cells with green fluorescence higher than particular intensity, it will be 
much help full to characterize these differentiated cells with “adrenergic” phenotype, 
especially for their electrophysiological properties. In addition, to achieve higher 
population of cardiomyocytes in the whole populations is also an important factor to get 
the same purpose, as current differentiation method can only achieve less percentage 
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of beating cells in the whole populations, the majority of beatings are spontaneous. 
Currently, growth factors, morphogenes, or some other small molecules have already 
been reported to stimulate cardiac differentiation [131]. The much purer populations of 
cardiomyocytes will form a more integrated network, and also the higher ratio for cells 
with green fluorescence,  thus when puromycin is introduced, the green fluorescent 
cells will well resist these drugs and more prone to survive, therefore, the enrichment of 
the recombinant “adrenergic” cells could be proceeded with higher success rate.  
 
 
 
 
 
 
 
 
 
89 
 
CHAPTER 5 : GENERATION OF KNOCK-IN TARGETING 
CONSTRUCT WITH SURFACE MARKER AS REPORTER GENE TO 
ACHIEVE PURE POPULATION OF ADRENERGIC CELLS BY 
MAGNETIC-ACTIVATED CELL SORTING 
 
5.1 Introduction 
 
The purpose of the project in this chapter was to establish the mESC lines with 
the features of adrenergic cells which can be purified by MACS. Previous studies have 
already shown that this was an efficient way to get purified ESCs with high yield even 
with very low input [38]. This method fits in our practical purpose as adrenergic 
progenitors only cover a small population of the cell populations during the embryonic 
heart development based on our hypothesis. 
As we mentioned in the Chapter 3, with Pnmt-nEGFP knock-in mouse as genetic 
model, we did identify cells with adrenergic phenotype during heart development, 
although practically this type of cells are very hard for identification as for several 
reasons. However, the same genetic strategy can also be used if other more efficient 
methods for cell separation or sorting are available. MACS is one of these strategies 
which is based on affinity based magnetic particle (beads) separation. It has been 
reported with many advantages compared with other sorting method and currently 
referred to as the “gold standard” tool for cell separations. In this chapter, we first used 
molecular biology tools to make the targeting construct in which the transcription of 
surface marker gene is under the control of Pnmt regulatory elements. This construct 
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was then electroporated into pluripotent mESCs, and the successful targeted cell clones 
will give us the capability of enrichment of adrenergic progenitor cells by MACS.  
Among various surface makers used for magnetic bead sorting, C-terminal 
deleted version of low-affinity nerve growth factor receptor (ΔLNGFR) owns many 
advantages. LNGFR is one of the neurotrophin receptor superfamilies and expressed 
mainly in central and peripheral nervous systems [132, 133], later on the expression is 
also found in other tissue and organs such as bone marrow stroma, mescenchymal 
cells and hair follicle stem cells  [134-136]. However, the truncated form of LNGFR is 
only expressed on cell membrane in addition to its human origin which make it an ideal  
cell surface marker. Since ΔLNGFR is not expressed in cells except the above 
mentioned, it will be a good candidate as an exogenous marker to tag the specific cells 
among mixed populations, then immunogenic magnetic beads conjugated with 
ΔLNGFR antibody (Provided by Miltenyi Biotech Inc.) can be used for isolation of these 
cells by MACS. Actually, it has already been reported that ΔLNGFR was used as a tag 
to monitor gene transduction non-invasively [41, 137] and also a marker for enrichment 
of specific cell populations by MACS [41, 138] or other methods such as FACS [139]. 
ΔLNGFR is also used in separation of various stem cells or progenitor cell populations 
and achieved with higher purities [38, 42, 136]. In addition, no obvious immune 
responses are found and cells maintain high viabilities and the capabilities of self-
renewal and full differentiations.  
The establishing of the targeting construct needs several sublcone steps based 
on the already available plasmids. The purpose of the subclone is to engineer these 
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plasmids and put the cDNA of ΔLNGFR and neomycin together, which are then inserted 
into the Pnmt 5’ regulatory sequences. The construct will be further engineered by 
addition of Diphtheria toxin A fragment (DTA) as negative selection marker. Therefore, 
theoretically any ΔLNGFR positive cells should be transcribed by Pnmt, then the 
adrenergic cells, no matter on which differentiation status they are, can be characterized 
and even separated from other cells by MACS. Thereafter, we will target YFP mESCs 
with this construct and obtained the positive cell clones by both positive and negative 
selection in order to find the corrected targeted mESCs in which the construct is 
“knocked-in” into the Pnmt locus by homologous recombination. After confirmation by 
genetic screen, these cells will be good model to determine the characteristics of 
adrenergic progenitor cells during cardiac differentiation, and eventually used for further 
exploration of their biological activities and roles during embryonic heart development.  
 
5.2 Materials and Methods 
 
5.2.1 Introduction of available plasmid constructs for subclone 
The purpose of the subclone is to get the correct targeting construct which we 
will put the Pnmt regulatory sequences in front of surface marker ΔLNGFR. The positive 
and negative marker should also be added and engineered into the same construct. 
The plasmids with our hand are as followings: 
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pMACS-LNGFR, 5445bp, which contains the cDNA of ΔLNGFR is provided by 
Miltenyi Bitotech.  
pPNMT, here referred to p458, which contained mouse genome 5’ Pnmt 
upstream regulatory sequences and also the downstream coding sequence, however, in 
front of the first base pair of coding sequence, an EcoRI site was created by Promega 
Mutagenesis kit, thus allowing us to insert the cDNA of interested gene as a marker 
whose expression would be exactly under the control of Pnmt regulatory sequences. 
The whole plasmid was 7.6kb which was already cloned as a SacI-SacI fragment, the 
base vector was pBluescript SK(+) from Clonetech.  
pFrt-Neo, here referred to p497, was a Frt flanked Neomycin cassette which was 
used as seclection marker in our studies. It was subcloned into pBluescript SK(+), with 
HindIII and SalI as single restriction site in the head and EcoRI in the bottom, all the 
three sites was used during our following subclone efforts. The whole plasmid was 
around 5kb and the Neomycin cassette was 2.1kb. 
pBJ101-DT, here referred to p8, originally from Knowles Lab of Wistar Institute, 
was an already subcloned plasmid which included negative selection marker Diphtheria 
toxin A fragment. The negative selection marker should be placed at one or both ends 
of the homologous DNA. The DTA sequence was under its own promoter, Herpes 
simplex Virus thymidine kinase (HSV-tk), which was a very strong promoter to drive the 
DTA expression. Thus, random insertion other than real homologous recombination was 
removed as DTA was not cleaved-off and exerting its toxicity. With this strategy, we can 
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reduce the number of clones for screening as the positive clones were enriched by this 
selection event [140].   
 
Figure 5-1. Skematic depiction of Diphtheria toxin A genetic component.  
 
EcoRI phosphorylated linkers (Catalog No. 26-3200-09) was from Gene Link TM, 
with total amount of 20μg and molecular weight at 3726, the sequence of which is 5’-
Pccggaattccgg-3’.  
All the restriction enzymes were from New England Laboratory (NEB), T-4 DNA 
ligase (M0202S), Klenow Fragments of DNA polymerase (M0210S), Antarctic 
Phosphatase (M0289S), Calf Intestinal Alkaline Phosphatase (M0290S) and λ-HindIII 
digest (M3012S) were also from NEB. Small amount of plasmid extraction was 
proceeded by QIAprep Spin Miniprep Kit (Qiagen, Catlog No. 27106), and large amount 
of plasmid extraction by Qiagen Plasmid Maxi Kit (Qiagen, Catlog No. 12163). QIAquick 
Gel Extraction Kit (Qiagen, Catlog No. 28706) and QIAquick PCR Purification Kit 
(Qiagen, Catlog No. 28104) were used for purification of DNA fragments from gel 
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extraction and enzymatic reaction separately. UltraPure™ Phenol:Chloroform:Isoamyl 
Alcohol (25:24:1, v/v) was from Invitrogen. Geneticin was from In vitrogen.  
XL-1 blue (Catlog No. 200249, Stratagene) competent cells were used for regular 
transformation with medium sized plasmid. For transformation of ligation product with 
large size DNA, XL-10 Gold Ultracompetent Cells (Catlog No. 200314) from Stratagene 
(Agilent Technology) and NEB10-beta competent cells (C3019H) from NEB were used.  
5.2.2 Generation of targeting construct Pnmt-ΔLNGFR-Neo-DTA 
5.2.2.1 Plasmid engineering to get ΔLNGFR and Neomycin dual cassettes  
pMACS-ΔLNGFR was cut with HindIII/XhoI/EcoRI (sequential digestion, first 
digested with HindIII/XhoI, then EcoRI) to pop up the 1.2kb ΔLNGFR fragment. The 
digested product was electrophoresed in 0.8% agarose gel and DNA band at 1.2kb was 
cut under UV, retrieved with the Qiagen gel extraction kit. 1μl of linearized DNA was 
further electrophoresed for identification of the correct size. Plasmid 497 was also cut 
with HindIII, blunted by Klenow larger fragment, then dephosphorylated by Antarctic 
Phosphatase (ARP), then purified by phenol/chloroform/isoamyl alcochol and 
precipitated in ethanol, finally re-suspended in pure distilled water. The concentration for 
the vector (497) and insert (ΔLNGFR) should be higher than 30 ng/μl, thus we can 
clearly see the band when 1-2μl DNA was loaded into the gel. 
Ligation reaction was followed the suggestions from NEB and detailed 
information was in the appendix B. The molar ratio of vector and insert was set between 
1:3 to 1:5, thus roughly 100 to 150ng DNA (Including both vector and insert) was added 
95 
 
together with ligation buffer and balanced with distilled water, around 0.2μl concentrated 
T4 ligase was added in the end to achieve a volume of 20μl for the reaction. The 
reaction product was incubated at 4°C overnight. On the second day, around 5μl 
reaction product was transformed into either NEB10-beta or XL-10 gold competent cells. 
When we got the colonies, we used miniprep to extract the plasmid from bacteria 
cultures from individual colony and identified their insertion and orientation by restriction 
digestion.  
The first subclone step yielded a plasmid around 6.2kb, with ΔLNGFR/Frt-Neo 
dual cassette cloned into pBluescript SK(+). Hence we called this plasmid p498. The 
plasmid was accurately confirmed by double digestion with one restriction site inside the 
insert (HpaI) and one outside the insert such as SacI or EcoRI. 
5.2.2.2 EcoRI site creation upstream of ΔLNGFR cDNA 
In the following step, theoretically we would subclone the ΔLNGFR/Frt-Neo 
fragment into plasmid p458. The insertion site was at EcoRI site, 3369bp downstream of 
the start of Pnmt regulatory elements. As for the p498, there was one EcoRI site outside 
of Neo cDNA, and in front of ΔLNGFR, there was only a SalI single restriction site. In 
consideration it was a large size subclone (3.25kb ΔLNGFR/Frt-Neo ligation with 10.6kb 
p458), it would be very less efficient for blunt ligation and this was confirmed by our 
previous efforts. So modification of the plasmid/insert was necessary in order to create 
cohesive site and its following ligation.  
Thus in this step, the p498 was engineered to achieve another cohesive EcoRI 
site in front of ΔLNGFR cDNA. In order to do this, p498 was linearized by SalI and 
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blunted by Klenow fragment. The linearized p498 was resuspended in distilled water 
and the proper amount of EcoRI phosphorylated linker (the linker was dissolved in 
around 89ul of distilled water to get concentration of 60pmol/μl, or around 225ng/μl. ) 
was added to make the molar ratio of linker to DNA at 50:1, then 2.5ul of 10x ligation 
buffer was added and the whole reaction buffer was adjusted to 24ul and then T4 DNA 
ligase was added. Through screening, we got the second plasmid which had two EcoRI 
site and named it p499. 
5.2.2.3 Subclone the ΔLNGFR-Neomycin casettes into Pnmt genomic locus 
Plasmid 499 was cut with EcoRI and BcgI (sequential digestion), the 3.25kb dual 
insert was thus isolated from the gel and purified. p458 was also cut with EcoRI, 
dephosphorylated and the ligation reaction was set up as mentioned above. The clones 
were identified by several steps. First, the extracted plasmids and p458 were loaded 
into gel together. The comparison of the band shift was made as the engineered 
plasmid with insertion should migrate a little slower than p458. The clones with slower 
migration were further checked by single digestion with EcoRI for insertion and double 
digestion with SacI/HpaI for their orientation. The correct clone was named as p461.  
5.2.2.4 Generation of targeting construct Pnmt-ΔLNGFR-Neo-DTA with addition 
of negative selection gene 
 
The negative selection marker was p8 (DTA), which was around 2.8kb as a SalI-
SalI fragment. p8 was cut with SalI, retrieved from the gel and purified. The plasmid 
p460 also had only one SalI site in the Multiple Cloning Site (MCS), as the other SalI 
site in p497 during previous subclone steps. The p461 was digested with SalI and 
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dephosphorylated. The molar ratio of the vector and insert was carefully chosen as this 
was a large size ligation. We tried different ratios from 1:1.5 to 1:2 and 1:3. The final 
targeting construct was confirmed by multiple restriction digestion, with both single and 
double enzymes involved. The plasmid was named Pnmt-ΔLNGFR-Neo-DTA, and 
referred to p462. The length of the final construct was 16.62kb.  
5.2.3 Generation of YFP mESCs knocked in with Pnmt-ΔLNGFR-Neo 
 
7AC5EYFP cells (SCRC-1033™ , available from ATCC) which was a R1 derived 
mESC line, was used for the generation of new mESCs with the Pnmt genomic locus 
knocked in by the above target construct. This mESC line showed yellow fluorescence 
as cDNA of EYFP was inserted into the genome and also kept the germ line 
competency which could be used for generation of genetic manipulated mice.  
mESC were maintained as described in previous chapters. Cells at early 
passages were used for electroporation. The p462 was linearized with BcgI and then 
purified, around 40μg DNA was resuspended in 30μl electroporation buffer and kept 
sterile. The electroporation parameter and detailed protocol was described in the 
Chapter 4 with proper control groups included.  
Geneticin (G-418 Sulfate) was used for selection of positive clones as it acts 
similar with neomycin but functional in eukaryotes. The concentration of G-418 during 
clone selection was 350μg/ml and drugs were added 1d after elctroporation and 
refreshed every other day. On day 5 to 6, apparently most of the cells were dead. After 
small patches of cells gradually came out and we will pick them out on day 10. The 
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criteria for good neomycin resistant clones were clearly reported before [141]. We 
picked up 84 colonies totally. The colonies were carefully frozen as stock for 
identification of correct homologous recombination by southern blot and PCR.  
 
5.3 Results 
 
5.3.1 Creation of Pnmt-ΔLNGFR-Neo-DTA targeting construct through series of 
subclone  
 
The schematic map of the plasmid, which was based on pBluescript SK(+), was 
described in Fig.2. The total length of the plasmid was 16623 base pairs which was 
illustrated in the map. Plasmid generated from individual step was characterized in 
orders by restriction analysis.  
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EcoRI
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BcgI delta LNGFR
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Figure 5-2. Schematic map of targeting construct Pnmt-ΔLNGFR-Neo-DTA. 
The length of each part of the plasmid was scaled to its size, with different colors 
representative of these component. White: the 5’ and 3’ of Pnmt genomic sequences; 
Dark blue; the cDNA of delta LNGFR; Pink, the cDNA of Neomycin resistance cassette; 
Red, DTA fragment; Light bluel: the pBluescript SK(+) plasmid.  
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5.3.1.1 Creation of plasmid with ΔLNGFR and Neomycin dual cassettes 
 
 
Figure 5-3. Restriction analysis of plasmid with insertion of ΔLNGFR and Neomycin 
resistance gene. 
The 4th through 7th lanes were restriction analysis of engineered plasmid (p498) with 
ΔLNGFR cDNA insertion. The 4th through 6th lanes are EcoRI, SalI and BamHI single 
digestion respectively, where the 7th lane was SacI/HpaI double digestion for 
confirmation of the orientation. The rightmost band was HindIII digest as DNA ladders. 
 
 
 
 
 
101 
 
5.3.1.2 Creation of plasmid with EcoRI restriction site on both end of ΔLNGFR 
and Neomycin cassettes 
 
 
Figure 5-4. Restriction analysis of plasmid with EcoRI site on both end of ΔLNGFR and 
Neomycin resistance gene.  
The first lane was HindIII digest as DNA ladder. The 2nd, 4th and 6th were p498, while 
the 3rd, 5th, 7th were p499 with correct EcoRI linker modification in front of ΔLNGFR. The 
2nd and 3rd lanes were BcgI single digestion, the 4th and 5th were EcoRI single digestion, 
the 5th lane showed p499 with successful addition of an EcoRI site thus two bands with 
similar size appeared. The 6th and 7th lanes were BcgI/EcoRI double digestion which 
made (ΔLNGFR+NeoR) cassette of p499 easily separated from the leftover fragment. 
This cassette was around 3.25kb. 
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5.3.1.3 Creation of plasmid with ΔLNGFR and Neomycin insertion into Pnmt 
genomic locus 
 
 
Figure 5-5. Restriction analysis of Pnmt-ΔLNGFR-Neo plasmid. 
p461 was analyzed by restriction digestion. The 1st lane was HindIII digest as DNA 
ladder, the 2nd and 3rd lane were EcoRI and SacI single digestion respectively, the 4th 
lane was SacI/HpaI double digestion which showed the correct orientation of the 
plasmid, the 5th was BamHI/HpaI double digestion, and the 6th lane was BglI digestion 
of p8.  
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5.3.1.4 Creation of Pnmt-ΔLNGFR-Neo-DTA by addition of DTA 
 
 
Figure 5-6. Restriction analysis of targeting construct Pnmt-ΔLNGFR-Neo-DTA.  
The 1st lane was HindIII digest as DNA ladder, the 2nd lane was undigested plasmid, the 
3rd was SacI digestion, 4th SacI/HpaI, 5th XhoI, 6th SalI/NotI, 7th EcoRI, all these analysis 
were for plasmid p462, and the last lane was undigested p461, the plasmid tested in the 
above figure.  
For the final targeting construct, EcoRI single digestion determined both insertion 
of DTA fragment and the orientation of the final DTA insertion. Although the DTA has its 
own promoter and enhancer, its expression during the homologous recombination didn’t 
need to follow the direction of the targeting construct. In this final plasmid, the direction 
of DTA transcription was the same with that of targeting construct.  
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5.3.2 Generation of mESC line knocked in with Pnmt-ΔLNGFR-Neo-DTA through 
homologous recombinations 
 
After electroporation of linearized p462 and screened by G418, we picked 84 
colonies, among which 75 colonies were continuously resistant to G418 and kept good 
proliferation rate. These clones were carefully maintained and each of them was frozen 
as back up for further identification of correct targeting.  
 
5.4 Discussion and Future Plans 
 
MACS technology is a well established method for cell separations. This 
technology utilize particular superparamagnetic particles, the diameters of which are 
around 50 nanometers. These magnetic particles are conjugated with specific 
antibodies, thus making labeling and purification of target cells available. As these 
particles are made of biodegradable matrix, so the enriched target cells don’t need to be 
removed from these particles, and these particles usually don’t alter the structure and 
activity of the labled cells. Since its discovery, this technology has already been applied 
in many types of cells, both from common populations to very rare cells which can’t be 
purified with high yield and purity with other methods such as FACS [38].  
MACS technology is based on above mentioned microbeads, and also MACS 
separator and MACS columns. When MACS column is placed in a separator, magnetic 
field is formed on the column matrix which can retain the cells labeled with microbeads. 
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There’re mainly two kinds of labeling strategies: the direct magnetic cell labeling for 
which cells are labeled with magnetic particles conjugated with specific antibodies, 
usually immunogenic for antigens on cell surface; the indirect magnetic cell labeling will 
label cells first tagged with primary antibodies which are either unconjugated, 
biotinylated or fluorochrome conjugated, and then relevant anti-immunoglobulin, anti-
biotin, strepatavidin or anti-fluorochrome microbeads are used for magnetic labeling. 
Since discovery, MACS has been widely employed for separation of many types of cell 
populations, such as Plasma cells from bone marrow [39], enrichment of specific 
spermatogonia from testis [142], separation of SSEA-4 (Undifferentiated ES cell surface 
marker) labeled human embryonic stem cells from heterogeneous populations [143, 
144]. In addition, MACS doesn’t affect the differentiation status of the initial cell input, for 
example, sorting of VCAM1 (Vascular cell adhesion molecule 1) positive cells from 
human ESC and human induced pluripotent stem cells (hiPSC) by MACS both achieved 
pure populations of VCAM1 positive cells, and these cells can well differentiate into 
functional cardiomyocytes [40]. In another study when ΔCD4 is used as surface marker, 
partial differentiated ES cells (day 3 after starting differentiation) could be purified by 
MACS, and the yield could still differentiate into all three germ layers (ectoderm, 
mesoderm and endoderm), elucidating the advantage of this strategy. Some reports 
showed that cells sorted by FACS had higher percentage of apoptotic like phenotypes 
[145, 146], however, there have been no reports so far for obvious cell damages of 
sorted cells by MACS.  
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In our studies, we successfully engineered the targeting construct with ΔLNGFR 
as the surface marker, the transcription of which is regulated by Pnmt sequences, thus 
isolation of these rare adrenergic progenitor cells from mixed cell populations will be 
technically doable.  LNGFR (CD271) conjugated microbeads are commercially 
alavailable from Miltenyi Biotec Company along with the separation kit (column and 
magnetic separator). The purification of these cells will be feasible if proper amounts of 
LNGFR microbeads are loaded with fixed number of “knocked-in” cells. Under various 
differentiation status (pluiripotent, partial differentiated, terminally differentiated into 
beating cardiomyocytes), cells will be pooled and proceeded with MACS.  We 
hypothesize that the expression of this surface marker would be strong enough to be 
detected by these antibody conjugated beads and cells would be separated from the 
column under magnetic conditions by positive selection, and the eluted cells will yield 
high concentration of positive cells, which can be confirmed by immunostaining and 
FACS. These sorted cells will be further characterized by their electrophysiological 
properties to see whether they’re matched to various cell types during cardiogenesis, 
whether they have the features similar to specific populations, such as progenitors from 
ventricles, atria and conduction systems. In addition, comparisons will be made among 
these cells, first to see whether ΔLNGFR’s expression is dependent on the 
differentiation status, such as the expression is negative or below detection under 
pluripotent status, however it will increase after cardiac differentiation, and under which 
status the expression is highest will also be determined, as this will indicate the peak 
function of Pnmt during this process. Provided that the in vitro evidence is convincing, 
the knock-in mouse strain will be established which will be an useful tool for further 
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identify and characterize the function of adrenergic cells during cardiovascular 
development and the compound mechanisms of regulation of cardiac growth, 
differentiation and other unknown functions regulated by Pnmt. Adrenergic cells from 
other extra-adrenal tissues can also be collected from this animal model, their functions 
will be uncovered to a deeper level.  
 
 
 
 
 
 
 
 
 
 
 
 
 
108 
 
CHAPTER 6 : SUMMARY 
 
The general purpose of this thesis was to develop and apply imaging modalities 
and other relevant tools to evaluate the efficacy of transgene expression in specific 
tissues in vivo and determine the how this transgene expression was correlated with the 
potential of induction of exogenous gene therapy, or explanation of an important 
biological phenomena during embryonic development. We will summarize each chapter 
as follows: 
In Chapter 2, we mainly use BLI as a particular non-invasive imaging tool, to 
determine its capability of evaluation of transgene expression by multiple gene delivery 
methods, and also characterization of genetic manipulated mESC in which luciferase 
reporter gene was transfected. Data clearly showed that beyond accurate detection of 
induced reporter gene expression, BLI possesses the advantage of detection of 
luminescence continuously in one single animal non-invasively, thus leading to more 
consistent conclusions for transgene evaluations and cost effectives. BLI has been 
confirmed useful in measurement of transgene expression in mouse skin, liver and 
heart introduced with reporter gene by biolistic and needle injection, in addition to the 
precise correlation of reporter gene expression and the number of pluripotent mESCs 
cells. Although with some limitations in the studies, BLI is deserved for evaluation of 
efficacy of other gene delivery methods, especially those with close to clinical 
applications, such as cardiac gene therapy strategies [63, 85]. With proper design, BLI 
is also efficient to characterize the engrafted cells, especially manipulated mESCs and 
hESCs into the damaged tissues, such as their locations, survival or migration patterns, 
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which are extremely important as cell-based therapies can systematically evaluated with 
no-bias, thus more convincing results related to this therapeutic strategy come out [147, 
148], which will dramatically reduce the conflicted results when ESC based engraftment 
for cell therapy are applied to repair the injured tissues. 
In Chapter 3 through 5, our main purpose was to characterize the catecholamine 
producing cells in different tissues and at different development stage. As adrenergic 
hormone deficiency will lead to fetal heart failure, in addition to the broad distribution of 
catecholamine production in tissues other than adrenal gland, those together prompted 
us to utilize genetic models to determine the location of these adrenergic cells and try to 
explore their functions too. We chose the most common reporter gene: EGFP as the 
tool and generated Pnmt-nEGFP mouse model. This model provided us detailed 
information for the adrenergic cells in various organs. The EGFP positive cells also 
expressed Pnmt in adult adrenal medullar chromaffin cells unambiguously 
demonstrated the accuracy of this genetic manipulation. In extention, we also checked 
EGFP expression in the fetal heart, although signal was weak and positive cells were 
also fewer, the positive EGFP cells together with EGFP expression from the Pnmt-
nEGFP mESCs showed that cells with adrenergic phenotype did exist during 
cardiogenesis. In order to further characterize this smaller population of cells, mainly in 
regard to its function, we relied on other methodologies to improve the resolution to get 
these cells available. As mentioned in Chapter 4, we used an RFP/GFP dual 
fluorescence plasmid as the reporter gene and let it stably incorporate into pluripotent 
mESCs with Pnmt-Cre background. The Cre activation during mESC differentiation 
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gave us the chance to observe whether the recombination arose, here illustrated by 
excision of flanked RFP coding sequence through Cre. Through this “Stop then go” 
strategy, we observed “to go”, referred to EGFP expressing cells in beating areas from 
15day cardiac differentiated mESCs, which further determined the adrenergic 
phenotype was tightly associated with cardiac differentiation. Based on these 
discoveries, systematic experiments are necessary to determine at which stage of 
differentiation these green fluorescent cells are concentrated, and whether the cell 
sorting combined with antibiotic resistance selection can yield relatively pure population 
of these cells. Should these cells available, it will be a big breakthrough as we can 
determine its function by both electrophysiology, molecular biology and also 
engraftment in vivo.  
The lessons from both Chapter 3 and Chapter 4 were focused on one point. The 
variable expression of targeted cells seemed common when fluorescent reporter gene 
was employed, although separate target construct was used in each chapter. For Pnmt-
nEGFP model, we found less number of EGFP cells compared with those of Pnmt 
expressing cells in adult adrenal medulla, which we didn’t know the exact answer with 
current data. Similar results were also found from other reports that even more 
diversified expression patterns existed from GFP transgenic mice with ubiquitous 
promoters [35]. This is so complicated due to many possible reasons. It’s deserved to 
determine the mechanisms leading to other cells targeted with EGFP but without 
detectable GFP expression. Gene silencing, inhibition by some post-translational 
modification such as methylation are among the potential mechanism. The limitations 
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from the created model from Chpater 4 mainly came from the heterogenicity of RFP 
expression in pluripotent mESCs. Partial reasons could come from the immature status 
of the HcRed1 as a protein tag, as other better performed version of HcRed mutants are 
still under investigation. In addition, more mechanism may also account for this 
heterogeneous expression pattern. Further characterization of Cre expression since 
cardiac differentiation will let us know the dynamics of its activity, and more genetic 
information about the expression of EGFP since differentiation will help us get 
comprehensive appreciation of this process and also the enrichment of these Pnmt 
expressing cells. 
Nevertheless, the above models show their capabilities in characterization of 
adrenergic cells, meantime, other strategies are also demanding which can overcome 
their shortages. Therefore, in the last chapter, I chose other reporter gene as alternative 
strategy to fulfill the same purpose of the previous two. It has been acknowledged that 
magnetic associated cell sorting is a far efficient way for isolation of rare population of 
cells compared with FACS [38], with higher yield and also higher concentration of 
positive cells when proper cell surface marker was chosen. In this chapter, the cDNA of 
human ΔLNGFR, a truncated low-affinity nerve growth factor receptor, was chosen as 
this marker, and engineered into Pnmt genomic locus which will recapitulate its 
expression in vivo, through homologous recombination, the targeted clones were 
collected and under identification. The correct targeted mESCs will enable us a powerful 
tool to determine the adrenergic cells during in vitro cardiac differentiation. At various 
differentiation stages (immature, partially mature and fully mature cardiomyocytes), the 
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input cells can be loaded into column under magnetic field and sorted. It will be great 
helpful if we can successfully sort the positive cells and do the comparison based on 
their expression of markers of cardiomyocyte, endothelial cells, fibroblast or other type 
of progenitor cells. As mentioned before, their proliferation, differentiation capability, 
electrical activity and performance after engraft into animal heart are also deserved for 
studies. This method is one of the best ways to accomplish the objective and we will 
eventually draw the convincing conclusion that whether this type of cells expressed in 
embryonic heart and also in other adult extra-adrenal organs have specific functions 
should the animal model is available.  
All the work in these chapters will lay the ground of basic biological knowledge of 
Pnmt expressing cells during embryonic development. The data we have and the 
anticipated results from new genetic models will make us understand more broadly 
about specific adrenergic cells expressed in tissues other than adrenal gland. These 
methodologies pave the way to isolated, characterize and determine their individual 
function in various organs.  
The reason of the long term pursuit for these adrenergic cells during embryonic 
heart development is we want to compare the identical and different features with those 
established cells which were sorted based on specific markers such as Isl-1, Sca-1, c-
Kit, and also other morphogens [69]. Although these cells have been tested and 
confirmed as origins of cardiac progenitor cells, it’s still lacking convincing data that 
these cells are the real cardiac progenitors, as most of the markers were also found in 
other type of progenitor cells. Pnmt expressing cells, although transiently expressed 
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during heart development, might also have some cross-over with expression of those 
above markers, the distinguishing between those cells and adrenergic cells will help us 
understand at which specific development stage do adrenergic hormone are involved in 
the regulation of cardiogenesis, and also the potential as target cells as therapeutic 
strategies for recovery of myocardium infarction and other cardiac repair.  
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APPENDIX A: COMPONENTS OF MEDIUM AND BUFFER FOR MOUSE 
EMBRYONIC STEM CELL CULTURES 
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Pluripotent ES cell growth medium 
DMEM (4.5g/L) 500ml 
Fetal Bovine Serum 90ml 
Penn/Strep 6ml 
Glutamx 5.8ml 
Non Essential Amino Acids 5.8ml 
2-mercaptoethanol 1.1 μl 
LIF    600μl 
 
ES cell differentiation medium 
DMEM (4.5g/L)  500ml 
Serum 90ml 
Penn/Strep 5.8ml 
L-glutamine 5.5ml 
Non Essential Amino Acids 5.8ml 
2- mercaptoethanol 1.1μl 
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Mouse embryonic fibroblasts (MEF) medium 
DMEM(4.5g/L)  500ml 
Penn/Strep 5.5ml 
Fetal bovine serum: 55ml 
 
ES cell Electroporation Buffer 50ml 
10x Hanks 5ml 
1M Hepes 1ml 
2-Mercaptoethanol 0.1ml 
1M NaOH 50μl 
Double distilled water 44ml 
Filtrate with 0.22μm filter by syringe and keep in -20°C 
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APPENDIX B: EXPERIMENTAL PROTOCOLS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
118 
 
Suclone for generatation of the targeting construct (Pnmt-ΔLNGFR-NeoR-DTA) 
Klenow Filling for p497, pΔLNGFR and p498 (pΔLNGFR+NeoR) 
   
DNA:      30μl 
dNTP (10X):   4μl 
NEB buffer 2:   1 μl 
Klenow Fragment:   4μl 
Room Temperature for 20mins, reaction was stopped by addition of EDTA to final 
concentration of 10mM, then heat inactivated at 70°C for 20mins.  
Note: dNTP (N0447S from NEB) stock solution was 10mM, and the working 
concentration in Klenow filling was 33μM, therefore, stock dNTP solution was first 
diluted 30 times to get the 10X concentrated solution (330μM) with distilled water and 
kept at -20°C. This solution was further diluted 10 times during the reaction to yield final 
working concentration at 33 μM. 
p497 dephosphorylation by Calf Intestinal Alkaline Phosphatase (CIP) 
DNA after Klenow filling:  5μl 
NEB buffer 3:  4μl 
dH2O  30μl 
CIP  0.2μl 
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Total reaction volume was around 40μl and the reaction was at 37°C for 30mins, then heat 
inactivated at 65°C for 45mins, and purified by Phenol/Chloroform/Isopropanol (25:24:1, v/v) 
and precipitated by ethanol.  
Ligation of p497 and ΔLNGFR 
Insert  4.2μl 
Vector  4.2μl 
Ligation Buffer (10X)  2μl 
Enzyme  0.8μl 
PEG8000 (40%)  4μl 
dH2O  5μl 
   
The molar ratio of insert (1.2kb ΔLNGFR and 5kb vector) was set at 5:1, the total 
amount of DNA in the reaction was less than 200ng. The reaction was incubated 
overnight at 16°C. On the second day, 5μl ligation product was used to transform into 
NEB 10-beta competent cells.  
During the second step of subclone, when 12bp double strand oligonucleotide (5’ 
phosphorylated EcoRI linker) was ligated with p498, the molar ratio of insert to vector 
was set at 50:1.  
The formula for the ligation of ΔLNGFR+NeoR with Pnmt genomic sequences was 
similar with the above listed reaction between p497 and ΔLNGFR, the insert/vector ratio 
was set at 5:1.  
120 
 
The formula for the ligatation of pPnmt-ΔLNGFR+NeoR (461) with DTA was similar with 
those above, only with the ratio of insert to vector reduced to 1.5-3 to 1, which could 
increase the frequence of the contact between insert and vector. 
 
β-galactosidase activity assay 
This protocol is used for detection of formalin fixed frozen sections, when tissues are 
transfected with plasmid expressing LacZ, the transfection effects can be detected by 
assay the activity of gene product of lacZ, β-galactosidase, which can catalyze the 
hydrolysis of β-galactosides (X-gal) to form the deposition of blue colors.  
X-gal Stock Solution (4% in DMF):  
      X-gal (5-bromo-4-chloro-3-indolyl- β-D-galactopyranoside)         20 mg 
      DMF (N, N Dimethylformamide)                                                                     0.5 ml  
Mix till complete dissolved, store at -20°C and protected from light 
X-gal Dilution Buffer:  
        Potassium Ferricyanide Crystalline (5mM)                   160 mg  
        Potassium Ferricyanide Trihydrate (5mM)                    210 mg  
        Magnesium Chloride (2mM)                                            20 mg  
        PBS                                                                                  100 ml  
121 
 
Mix well and stored at 4 ºC, protected from light.  Warm to 37°C prior to use.  
X-gal Working Solution:  
      First warm X-gal dilution buffer to 37 ºC to prevent precipitation of X-gal.  
      Then dilute X-gal stock solution 1:40 in warmed X-gal dilution buffer (keep buffer 
warm at 37 C before applying to slides).   
Procedure:  
1.       Cryostat frozen sections and fix with cold 2%formalin (4 ºC) for  30minutes.  
2.       Wash slides with PBS for three times with5 minutes each and then rinse in 
distilled  water.  
3.       Incubate slides in X-gal working solution at 37°C for 24 hours (Put wet Kimwipes 
around     the tissue to avoid the slides from).  
4.       Rinse sections in PBS for 3x5 minutes  
5.       Rinse with distilled water briefly.  
6.       Counterstain with acidified aqueous Eosin Y Solution for 2 minutes.  
7.       Rinse in distilled water.  
8.       Mount the slides with aqueous mounting medium. 
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